Anti-influenza antibody

MYPI2025006506A0Undetermined Publication Date: 2024-10-26SUMITOMO PHARMA CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025006506
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-26
Filing Date
2024-04-25
Publication Date
2024-10-26

AI Technical Summary

Technical Problem

Current influenza vaccines induce strain-specific antibodies that are ineffective against antigenically mutated viruses, limiting their protective effects against various influenza A virus strains due to high structural variation in the hemagglutinin globular region.

Method used

Development of monoclonal antibodies or antibody fragments that bind to the conserved long alpha helix region of the hemagglutinin stem region of influenza A virus, providing broad-spectrum protection across different subtypes and phylogenetic groups, and methods for detecting or quantifying influenza vaccine antigens and antibodies for quality control and efficacy evaluation.

Benefits of technology

The monoclonal antibodies demonstrate wide-ranging binding activity against multiple influenza A virus subtypes, offering enhanced protection and enabling effective quality control and evaluation of vaccine efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025006506_DRAWING_001
    Figure PI2025006506_DRAWING_001
  • Figure PI2025006506_DRAWING_002
    Figure PI2025006506_DRAWING_002
  • Figure PI2025006506_DRAWING_003
    Figure PI2025006506_DRAWING_003
Patent Text Reader

Abstract

The present application provides a monoclonal antibody or an antibody fragment thereof, wherein the monoclonal antibody or antibody fragment thereof binds to a hemagglutinin stem region (HA stem region) of an influenza A virus.
Need to check novelty before this filing date? Find Prior Art

Description

anti-influenza antibodies

[0001] The present disclosure relates to monoclonal antibodies or antibody fragments that bind to influenza virus-derived antigens.

[0002] Influenza viruses are classified into types A, B, and C based on antigenic differences in the viral nucleoprotein (NP) and matrix protein (M1) (Non-Patent Document 3). Types A and B are the viruses that repeatedly circulate among humans, and all viruses that have caused global pandemics are type A (Non-Patent Document 1). Both influenza A and B viruses possess hemagglutinin (hereinafter, hemagglutinin may be referred to as "HA"), which functions to invade host cells. There are 18 types of hemagglutinin in type A (H1 to H18), and based on the genetic homology of the hemagglutinin, influenza A viruses are classified into two phylogenetic groups (phylogenetic groups 1 and 2) (Non-Patent Document 2).

[0003] Hemagglutinin is structurally and functionally divided into two regions, the globular head region and the stem region. The globular head region is exposed to the outside of the viral membrane, and antibodies induced by the administration of currently available influenza HA vaccines bind to this globular head region and inhibit viral binding to cell surfaces, thereby exerting a protective effect against infection. However, because the globular head region of hemagglutinin is the region that undergoes the most structural variation among viral strains, many of the induced antibodies are "virus strain-specific antibodies" that are effective only against specific strains and cannot bind to antigenically mutated viral strains, resulting in a lack of protective effect against infection (Patent Document 1).

[0004] In recent years, "cross-protective antibodies" have been reported as protective antibodies that are different from the above-mentioned virus strain-specific antibodies and that recognize conserved epitopes that are resistant to antigenic mutation and exhibit broad-spectrum protective effects against infection (Non-patent Documents 2 and 3).

[0005] Japanese Patent Publication (A) JP 2019-43937

[0006] Viruses Vol. 69, No. 2, pp. 161-168, 2019 Front. Immunol. (2018) 9:116 Nat. Commun. (2019) 10:3883

[0007] An object of the present disclosure is to provide a monoclonal antibody or antibody fragment thereof that is effective for treating or preventing influenza A virus infection. Another object of the present disclosure is to provide a method for detecting or quantifying influenza A vaccine antigens for purposes such as quality control during influenza A vaccine production, and a method for detecting or quantifying influenza antibodies for purposes such as efficacy evaluation in vaccine clinical development.

[0008] As a result of extensive research, the present inventors have obtained multiple monoclonal antibodies that bind to the LAH (long alpha helix) region of the hemagglutinin stem region (hereinafter sometimes referred to as the HA stem region, stem region, or stem) of influenza A virus, and have found antibodies from these monoclonal antibodies that are effective in protecting animals against influenza virus infection. Furthermore, the inventors have found that some antibodies have a broad binding activity against influenza A virus HA subtypes belonging to phylogenetic group 1 and a broad binding activity against influenza A virus HA subtypes belonging to phylogenetic group 2. Furthermore, the inventors have discovered a method for detecting or quantifying influenza A vaccine antigens (particularly membrane-fusion influenza vaccine antigens) using these antibodies, as well as a method for detecting or quantifying influenza antibodies for purposes such as evaluating the efficacy of vaccines in clinical development.

[0009] The present disclosure provides, for example, the following: [Item 1] A monoclonal antibody or antibody fragment thereof that binds to the hemagglutinin stem region (HA stem region) of influenza A virus. [Item 2] The monoclonal antibody or antibody fragment thereof according to Item 1, that binds to a peptide consisting of at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 18. [Item 3] The monoclonal antibody or antibody fragment thereof according to Item 1 or 2, that binds to the LAH (long alpha helix) region of the HA stem region. [Item 4] The monoclonal antibody or antibody fragment thereof according to any one of Item 1 to 3, that binds to a peptide consisting of at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 36. [Item 5] The monoclonal antibody or antibody fragment thereof, CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87 in which one or two amino acid residues are independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, 64, 72, 80, and 88; a heavy chain variable region comprising a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89, with one or two amino acid residues independently substituted, deleted, added, or inserted; and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89, with one or two amino acid residues independently substituted, deleted, added, or inserted; and / orCDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90 in which one or two amino acid residues are independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, 67, 75, 83, and 91; Item 5. The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 4, comprising: a light chain variable region comprising a CDR2 comprising an amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted in a selected amino acid sequence; and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92, or an amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted in an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92. [Item 6] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 5, wherein the monoclonal antibody or antibody fragment thereof comprises: a heavy chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, 64, 72, 80, and 88, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89; and / or a light chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, 67, 75, 83, and 91, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92. [Item 7] The monoclonal antibody or antibody fragment thereof isItem 7. The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 6, comprising: a heavy chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, and 63, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, and 64, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, and 65; and / or a light chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, and 66, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, and 67, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, and 68. [Item 8] The monoclonal antibody or antibody fragment thereof according to Items 1 to 6, wherein the monoclonal antibody or antibody fragment thereof comprises: a heavy chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 71, 79, and 87, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 80, and 88, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 81, and 89; and / or a light chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 82, and 90, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 75, 83, and 91, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76, 84, and 92. [Item 9] (a) a heavy chain variable region comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 47 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 48 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 49 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence; and / ora light chain variable region comprising: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 50 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (b) a CDR1 comprising the amino acid sequence of SEQ ID NO: 50 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (c) a CDR2 comprising the amino acid sequence of SEQ ID NO: 51 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 57 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 58 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a CDR2 comprising the amino acid sequence of SEQ ID NO: 59 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 60 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (c) a CDR1 comprising the amino acid sequence of SEQ ID NO: 63 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, CDR2 comprising the amino acid sequence of SEQ ID NO: 64 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence; anda heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 65 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 66 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a CDR2 comprising the amino acid sequence of SEQ ID NO: 67 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 68 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (d) a CDR1 comprising the amino acid sequence of SEQ ID NO: 71 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a heavy chain variable region comprising: a CDR2 comprising the amino acid sequence of SEQ ID NO: 72 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 73 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 74 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 75 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a light chain variable region comprising: a CDR3 comprising the amino acid sequence of SEQ ID NO: 76 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; CDR1 comprising the amino acid sequence of SEQ ID NO: 79 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence;a heavy chain variable region comprising: a CDR2 comprising the amino acid sequence of SEQ ID NO: 80, or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 81, or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 82, or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 83, or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a light chain variable region comprising: a CDR3 comprising the amino acid sequence of SEQ ID NO: 84, or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR1 comprising the amino acid sequence of SEQ ID NO: 87 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 88 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 89 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 90 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 91 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; [Item 10] (a') The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 5, comprising a light chain variable region including a CDR3 comprising the amino acid sequence of SEQ ID NO: 92 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence.(b') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 55, CDR2 comprising the amino acid sequence of SEQ ID NO: 56, and CDR3 comprising the amino acid sequence of SEQ ID NO: 57, and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 58, CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and CDR3 comprising the amino acid sequence of SEQ ID NO: 60; (c') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 63, CDR2 comprising the amino acid sequence of SEQ ID NO: 64, and CDR3 comprising the amino acid sequence of SEQ ID NO: 65, and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 66, (d') a light chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 71, a CDR2 comprising the amino acid sequence of SEQ ID NO: 72, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 73, and / or a light chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 74, a CDR2 comprising the amino acid sequence of SEQ ID NO: 75, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 76; (e') a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or (f') a CDR1 comprising the amino acid sequence of SEQ ID NO: 87, a CDR2 comprising the amino acid sequence of SEQ ID NO: 88, and a heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 89, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 90;The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 6, comprising a light chain variable region comprising CDR2 comprising the amino acid sequence of SEQ ID NO: 91, and CDR3 comprising the amino acid sequence of SEQ ID NO: 92. [Item 11] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 6, comprising: a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 47, CDR2 comprising the amino acid sequence of SEQ ID NO: 48, and CDR3 comprising the amino acid sequence of SEQ ID NO: 49; and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 50, CDR2 comprising the amino acid sequence of SEQ ID NO: 51, and CDR3 comprising the amino acid sequence of SEQ ID NO: 52. [Item 12] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 6, wherein the monoclonal antibody or antibody fragment thereof comprises: a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 55, CDR2 comprising the amino acid sequence of SEQ ID NO: 56, and CDR3 comprising the amino acid sequence of SEQ ID NO: 57; and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 58, CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and CDR3 comprising the amino acid sequence of SEQ ID NO: 60. [Item 13] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 6, wherein the monoclonal antibody or antibody fragment thereof comprises: a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 63, CDR2 comprising the amino acid sequence of SEQ ID NO: 64, and CDR3 comprising the amino acid sequence of SEQ ID NO: 65; and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 66, CDR2 comprising the amino acid sequence of SEQ ID NO: 67, and CDR3 comprising the amino acid sequence of SEQ ID NO: 68. [Item 14] The monoclonal antibody or antibody fragment thereof comprises: a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 71, CDR2 comprising the amino acid sequence of SEQ ID NO: 72, and CDR3 comprising the amino acid sequence of SEQ ID NO: 73; and / or CDR1 comprising the amino acid sequence of SEQ ID NO: 74, CDR2 comprising the amino acid sequence of SEQ ID NO: 75, andItem 15. The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 6, comprising: a light chain variable region comprising CDR3 comprising the amino acid sequence of SEQ ID NO: 76. [Item 15] The monoclonal antibody or antibody fragment thereof according to Items 1 to 6, comprising: a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 79, CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and CDR3 comprising the amino acid sequence of SEQ ID NO: 81; and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 82, CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and CDR3 comprising the amino acid sequence of SEQ ID NO: 84. [Item 16] The monoclonal antibody or antibody fragment thereof according to Items 1 to 6, wherein the monoclonal antibody or antibody fragment thereof comprises: a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 87, CDR2 comprising the amino acid sequence of SEQ ID NO: 88, and CDR3 comprising the amino acid sequence of SEQ ID NO: 89; and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 90, CDR2 comprising the amino acid sequence of SEQ ID NO: 91, and CDR3 comprising the amino acid sequence of SEQ ID NO: 92. [Item 17] (a'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 53, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 54; (b'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 61, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 62; (c'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 69, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 70; (d'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 77, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 78;(e'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 85, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 86; or (f'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 93, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 94. (c''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 69 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 70; (d''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 77 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 78; (e''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 85 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; or (f''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 93 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94. [Item 19] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 18, comprising: (a''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 54; (b''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 61, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 62; or (c''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 69, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 70. [Item 20] (d''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 77, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 78;(e''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 85, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86; or (f''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 93, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94. [Item 21] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 10, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 53, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 54. [Item 22] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 10, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 61, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 62. [Item 23] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 10, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 69, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 70. [Item 24] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 10, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 77 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 78. [Item 25] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 10, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 85 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 86. [Item 26] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 10, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 93 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94. [Item 27] ​​A monoclonal antibody or antibody fragment thereof that competes with the monoclonal antibody or antibody fragment thereof according to any one of Items 5 to 26 for binding to the HA stem region. [Item 28] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 27, which binds to the HA stem regions of two or more influenza virus HA subtypes. [Item 29] Binds to the HA stem region of influenza A virus HA subtype belonging to phylogenetic group 1, andThe monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 28, which binds to the HA stem region of an influenza A virus HA subtype belonging to phylogenetic group 2. [Item 29'] The monoclonal antibody or antibody fragment thereof according to any one of Items 15, 16, 25 and 26, which binds to the HA stem region of an influenza A virus HA subtype belonging to phylogenetic group 1 and also binds to the HA stem region of an influenza A virus HA subtype belonging to phylogenetic group 2. [Item 30] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 29, which has the ability to protect against influenza A virus infection. [Item 31] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 30, which is a murine antibody, chimeric antibody, humanized antibody or fully human antibody, or a fragment thereof. [Item 32] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 7, 9 to 13, 17 to 19, 21 to 23 and 27 to 31, which is a murine antibody or a fragment thereof. [Item 32'] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 7, 9 to 13, 17 to 19, 21 to 23, and 27 to 31, which is a chimeric antibody or a fragment thereof. [Item 33] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 18, 20, and 24 to 31, which is a fully human antibody or a fragment thereof. [Item 34] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 33, which comprises a modified constant region. [Item 35] The monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 34, which is conjugated to a drug. [Item 36] A pharmaceutical composition for treating or preventing influenza A virus infection, comprising the monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 35. [Item 37] The pharmaceutical composition according to Item 36, wherein the monoclonal antibody or antibody fragment thereof is the monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 18, 20, 24 to 31, or 33 to 35. [Section 38]The pharmaceutical composition according to paragraph 36, wherein the monoclonal antibody or antibody fragment thereof is the monoclonal antibody or antibody fragment thereof according to any one of paragraphs 8, 14 to 16, 20, and 24 to 26. [Item 39] The monoclonal antibody or antibody fragment thereof according to any one of paragraphs 1 to 35, for use in treating or preventing influenza A virus infection. [Item 40] A method for treating or preventing influenza A virus infection, comprising administering to a subject the monoclonal antibody or antibody fragment thereof according to any one of paragraphs 1 to 35. [Item 41] Use of the monoclonal antibody or antibody fragment thereof according to any one of paragraphs 1 to 35 in the manufacture of a medicament for treating or preventing influenza A virus infection. [Item 42] Use of the monoclonal antibody or antibody fragment thereof according to any one of paragraphs 1 to 35 for treating or preventing influenza A virus infection. [Item 43] The pharmaceutical composition of any one of Items 36 to 38, the monoclonal antibody or antibody fragment thereof of Items 39, the method of Items 40, the use of Items 41, or the use of Items 42, wherein the influenza A virus infection is an infection caused by an influenza A virus HA subtype belonging to phylogenetic group 1, and an infection caused by an influenza A virus HA subtype belonging to phylogenetic group 2. [Item 44] The pharmaceutical composition of any one of Items 36 to 38, the monoclonal antibody or antibody fragment thereof of Items 39, the method of Items 40, the use of Items 41, or the use of Items 42, wherein the influenza A virus infection is an infection caused by an influenza A virus HA subtype belonging to phylogenetic group 1 and / or an infection caused by an influenza A virus HA subtype belonging to phylogenetic group 2. [Item 45]The pharmaceutical composition according to Paragraph 36, the monoclonal antibody or antibody fragment thereof according to Paragraph 39, the method according to Paragraph 40, the use according to Paragraph 41, or the use according to Paragraph 42, wherein the monoclonal antibody or antibody fragment thereof is the monoclonal antibody or antibody fragment thereof according to any one of Paragraphs 1 to 11, 14 to 21, and 24 to 35, and the influenza virus infection is an infection caused by an influenza A virus HA subtype belonging to phylogenetic group 2. [Paragraph 46] The pharmaceutical composition, monoclonal antibody or antibody fragment thereof, method, or use according to Paragraph 45, wherein the influenza virus infection is an infection caused by an influenza A virus H3 or H7 subtype. [Paragraph 47] The pharmaceutical composition, monoclonal antibody or antibody fragment thereof, method, or use according to Paragraph 45, wherein the influenza virus infection is an infection caused by an influenza A virus H3 subtype. [Paragraph 48] The pharmaceutical composition, monoclonal antibody or antibody fragment thereof, method, or use according to Paragraph 45, wherein the influenza virus infection is an infection caused by an influenza A virus H7 subtype. [Item 49] The pharmaceutical composition of Item 36, the monoclonal antibody or antibody fragment thereof of Item 39, the method of Item 40, the use of Item 41, or the use of Item 42, wherein the monoclonal antibody or antibody fragment thereof is the monoclonal antibody or antibody fragment thereof of any one of Item 1 to 10, 12, 13, 15 to 20, 22, 23, or 25 to 35, and the influenza virus infection is an infection caused by an influenza A virus of an HA subtype belonging to phylogenetic group 1. [Item 50] The pharmaceutical composition, monoclonal antibody or antibody fragment thereof, method, or use of Item 49, wherein the influenza virus infection is an infection caused by an influenza A virus of subtype H1 or H5. [Item 51] The pharmaceutical composition, monoclonal antibody or antibody fragment thereof, method, or use of Item 49, wherein the influenza virus infection is an infection caused by an influenza A virus of subtype H1. [Item 52] The pharmaceutical composition, monoclonal antibody or antibody fragment thereof, method, or use according to Item 49, wherein the influenza virus infection is an infection caused by influenza A virus subtype H5. [Item 53]A method for detecting or quantifying a membrane-fused influenza HA antigen, comprising contacting a sample with the monoclonal antibody or antibody fragment thereof according to any one of Items 1 to 35. [Item 54] The monoclonal antibody or antibody fragment thereof comprises: (a) a heavy chain variable region comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 47 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 48 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 49 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 50 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 51 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (b) a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 52 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (c) a CDR1 comprising the amino acid sequence of SEQ ID NO: 55 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (d) a CDR2 comprising the amino acid sequence of SEQ ID NO: 56 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and (e) a heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 57 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or (f) a CDR1 comprising the amino acid sequence of SEQ ID NO: 58 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence.(c) a light chain variable region comprising a CDR2 comprising the amino acid sequence of SEQ ID NO: 59 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 60 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (d) a light chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 63 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising the amino acid sequence of SEQ ID NO: 64 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 65 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a light chain variable region comprising: (d) a CDR1 comprising the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (e) a CDR1 comprising the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (f) a light chain variable region comprising: (i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 71 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (ii) a CDR2 comprising the amino acid sequence of SEQ ID NO: 72 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and / ora light chain variable region comprising: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and (c) a light chain variable region comprising: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 79 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 81 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 82 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a CDR2 comprising the amino acid sequence of SEQ ID NO: 83 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 84 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; (f) a CDR1 comprising the amino acid sequence of SEQ ID NO: 87 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, CDR2 comprising the amino acid sequence of SEQ ID NO: 88 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence; anda heavy chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 89 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 90 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a CDR2 comprising the amino acid sequence of SEQ ID NO: 91 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 92 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; or (g) a CDR1 comprising the amino acid sequence of SEQ ID NO: 39 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, 54. The method of any one of claims 1 to 4, wherein the monoclonal antibody or antibody fragment thereof is a heavy chain variable region comprising: a CDR2 comprising the amino acid sequence of SEQ ID NO: 40 or the amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 41 or the amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted; and / or a light chain variable region comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 42 or the amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 43 or the amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted; and a light chain variable region comprising: a CDR3 comprising the amino acid sequence of SEQ ID NO: 44 or the amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted. [Item 55] The method according to Item 53 or 54, wherein the monoclonal antibody or antibody fragment is a combination of the first antibody and the second antibody described below.First antibody) The monoclonal antibody or antibody fragment according to any one of Items 1 to 35; or a monoclonal antibody or antibody fragment, wherein the heavy chain variable region comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 39, CDR2 comprising the amino acid sequence of SEQ ID NO: 40, and CDR3 comprising the amino acid sequence of SEQ ID NO: 41, and the light chain variable region comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 42, CDR2 comprising the amino acid sequence of SEQ ID NO: 43, and CDR3 comprising the amino acid sequence of SEQ ID NO: 44; Second antibody) A monoclonal antibody or antibody fragment, different from the first antibody, which binds to a peptide to which the first antibody can bind, wherein the second antibody is a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 18.

[0010] The present disclosure provides a monoclonal antibody or antibody fragment thereof that binds to the HA stem region of influenza virus, and a pharmaceutical composition for treating or preventing influenza virus infection, and a method for detecting or quantifying a universal influenza vaccine antigen derived from hemagglutinin, using the monoclonal antibody or antibody fragment thereof of the present disclosure.

[0011] FIG. 1 shows a graph in which the ELISA measurement value (absorbance) of each antibody is on the vertical axis and the reciprocal of the antibody concentration is on the horizontal axis, and the area under the curve (AUC) obtained from each curve for clones 1 to 7 is shown. From left: A / X-31(H3N2), A / Victoria / 361 / 2011 (H3N2), A / Singapore / INFIMH-16-0019 / 2016 (H3N2), A / Kansas / 14 / 2017 (H3N2), A / Puerto Rico / 8 / 1934 (H1N1), A / Narita / 1 / 2009 (H1N1pdm09), A / Michigan / 45 / 2015 (H1N1pdm09), A / Brisbane / 02 / 2018 (H1N1pdm09), A / NIBRG-14 (H5N1), A / Anhui / 1 / 2013 (H7N9). Figure 2 shows a heat map of AUC calculated from ELISA measurements (absorbance) for clones 6 and 7. Figure 3 shows a graph for clone 6, with absorbance plotted on the vertical axis and logarithmic antibody concentration plotted on the horizontal axis, and the antibody concentration corresponding to the midpoint (IC50) of the resulting sigmoid curve defined as 1 arbitrary titer (AU / mL). Figure 4 shows a graph with absorbance plotted on the vertical axis and logarithmic titer plotted on the horizontal axis, with the titer calculated for clone 5. Figure 5 shows the protective ability against infection with the H1N1pdm09 strain in the PBS-administered group and the monoclonal antibody (clone 3, clone 4, clone 6, clone 7)-administered groups, with the vertical axis representing weight change rate and the horizontal axis representing days after infection. Figure 6 shows the protective ability against infection with the H1N1pdm09 strain in the PBS-administered group and the monoclonal antibody (clone 3, clone 4, clone 6, clone 7)-administered groups, with the vertical axis representing survival rate and the horizontal axis representing days after infection. Figure 7 shows the protective ability against H3N2 infection in the PBS-administered group and the monoclonal antibody (clone 6, clone 7)-administered group, with the vertical axis representing the rate of weight change and the horizontal axis representing the number of days after infection. Figure 8 shows the protective ability against H3N2 infection in the PBS-administered group and the monoclonal antibody (clone 6, clone 7)-administered group, with the vertical axis representing the survival rate and the horizontal axis representing the number of days after infection.Figure 9 shows the results of slot blot detection of H1 fusion influenza HA antigen using clone 3 and measurement of a dilution containing H1 fusion influenza HA antigen (serial dilution of a 300 ng / mL solution at a common ratio of 1.6; 45.8 ng / mL to 300 ng / mL). Figure 10 shows the results of slot blot detection of H3 fusion influenza HA antigen using clone 1 and measurement of a dilution containing H3 fusion influenza HA antigen (serial dilution of a 300 ng / mL solution at a common ratio of 1.6; 45.8 ng / mL to 300 ng / mL). Figure 11 shows the results of ELISA detection of H1 fusion influenza HA antigen using clone 3 and measurement of a dilution containing H1 fusion influenza HA antigen (serial dilution of a 2000 ng / mL solution at a common ratio of 3; 34 pg / mL to 2000 ng / mL). FIG. 12 shows the results of detection of the H3 fusion influenza HA antigen by ELISA using clone 1 and measurement of a dilution containing the H3 fusion influenza HA antigen (a 2000 ng / mL solution serially diluted at a common ratio of 3; 34 pg / mL to 2000 ng / mL).

[0012] In this specification, the abbreviations for amino acids, (poly)peptides, (poly)nucleotides, etc., are in accordance with the IUPAC-IUB rules [IUPAC-IUB Communication on Biological Nomenclature, Eur. J. Biochem., 138:9(1984)], "Guidelines for the Preparation of Specifications Including Nucleotide Sequences or Amino Acid Sequences" (edited by the Japan Patent Office), and conventional symbols used in the relevant fields.

[0013] In the present disclosure, the binding of an antibody / antibody fragment to a specific HA stem region (or LAH region) means that the antibody / antibody fragment has an epitope in that region. Whether an antibody / antibody fragment binds to a specific HA stem region (or LAH region) can be confirmed by a commonly used method, for example, by examining whether it binds to a peptide (e.g., a synthetic peptide) corresponding to the amino acid sequence of the specific HA stem region (or LAH region) or a part of the specific amino acid sequence, similar to the method described in the Examples of the present application. The peptide used in the binding assay may have an amino acid sequence such as a signal peptide or a purification tag added, as long as it does not affect the results of the binding assay.

[0014] In the present disclosure, the binding of an antibody / antibody fragment to a peptide consisting of a predetermined amino acid sequence means that the antibody / antibody fragment has an epitope in the peptide consisting of that amino acid sequence. Whether an antibody / antibody fragment binds to a peptide consisting of a predetermined amino acid sequence can be confirmed by a commonly used method, for example, by examining whether it binds to a peptide (e.g., a synthetic peptide) corresponding to the predetermined amino acid sequence or a part of the predetermined amino acid sequence, as in the method described in the Examples of the present application. The peptide used in the binding assay may have an amino acid sequence such as a signal peptide or a purification tag added, as long as it does not affect the results of the binding assay.

[0015] As used herein, an epitope is a region of an antigen to which an antibody binds. An epitope may contain chemically active surface groups, such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and may have a characteristic three-dimensional structure and / or a characteristic charge. As used herein, a monoclonal antibody or antibody fragment can be said to specifically bind to an antigen or epitope when it preferentially recognizes that antigen or epitope in a mixture of antigenic substances such as proteins and peptides.

[0016] Epitope analysis can be performed by various methods (Epitope Mapping Protocols / Second Edition, Mike Schutkowski, Ulrich Reineke, Ann NY AcadSci. 2010 Jan; 1183:267-87.) More detailed epitope analysis can be performed, for example, by Western blotting using polypeptide fragments.

[0017] In one aspect, the present disclosure provides a monoclonal antibody (hereinafter sometimes referred to as the "monoclonal antibody of the present disclosure") or antibody fragment (hereinafter sometimes referred to as the "antibody fragment of the present disclosure") that binds to the hemagglutinin stem region (HA stem region) of influenza A virus. The amino acid sequence of the HA stem region may vary depending on the HA subtype, strain, etc., but in this disclosure, "an antibody / antibody fragment binds to the HA stem region of an influenza virus" means that the antibody / antibody fragment can bind to at least one type of HA stem region. Whether an antibody / antibody fragment binds to the HA stem region of an influenza virus can be confirmed by a commonly used method, for example, by examining whether it binds to a peptide (e.g., a synthetic peptide) corresponding to the amino acid sequence of the HA stem region or a portion thereof, similar to the method described in the Examples of the present application.

[0018] In one embodiment, the epitope of the monoclonal antibody / antibody fragment of the present disclosure consists of 5 to 20 amino acid residues present in the amino acid sequence of the HA stem region. In the present disclosure, "influenza virus" may refer to influenza A virus.

[0019] Examples of amino acid sequences of HA stem regions include the amino acid sequences of SEQ ID NOs: 1 to 18. The amino acid sequences of SEQ ID NOs: 1 to 18 are the amino acid sequences of the HA stem regions of predetermined strains of subtypes H1 to 18, respectively. Although the amino acid sequences of the HA stem regions of influenza A viruses are highly conserved, there may be slight differences depending on the subtype, strain, etc., and monoclonal antibodies or antibody fragments thereof that bind to amino acid sequences of HA stem regions other than the amino acid sequences of SEQ ID NOs: 1 to 18 are also included in the monoclonal antibodies / antibody fragments of the present disclosure.

[0020] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-18 or an amino acid sequence having at least 50% (e.g., at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 99%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-18.

[0021] The HA stem region is known to contain an α-helical structure (long alpha helix (LAH) region) of approximately 55 residues. Therefore, "binding to the HA stem region of influenza A virus" includes "binding to the LAH region of the HA stem region." In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to the LAH (long alpha helix) region of the HA stem region. Whether an antibody / antibody fragment binds to the LAH region can be confirmed by a commonly used method, for example, by examining whether it binds to a peptide corresponding to the amino acid sequence of the LAH region or a portion thereof, similar to the method described in the Examples of the present application.

[0022] In one embodiment, the epitope of the monoclonal antibody / antibody fragment of the present disclosure consists of 5 to 20 amino acid residues present in the amino acid sequence of the LAH region.

[0023] Examples of amino acid sequences of the LAH region include the amino acid sequences of SEQ ID NOs: 19 to 36. The amino acid sequences of SEQ ID NOs: 19 to 36 are the amino acid sequences of the LAH region in SEQ ID NOs: 1 to 18, respectively. Although the amino acid sequence of the LAH region is highly conserved among HA stem regions, there may be differences depending on subtypes, strains, etc., and monoclonal antibodies or antibody fragments thereof that bind to amino acid sequences of LAH regions other than the amino acid sequences of SEQ ID NOs: 19 to 36 (e.g., the amino acid sequences of SEQ ID NOs: 37, 38, and 95 to 98) are also included in the monoclonal antibodies / antibody fragments of the present disclosure.

[0024] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 36 or an amino acid sequence having at least 90% (e.g., at least 95%, at least 97%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 36. In a further embodiment, the monoclonal antibody / antibody fragment binds to an epitope consisting of several to a dozen amino acids that are common or similar to an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 36 or an amino acid sequence having at least 90% (e.g., at least 95%, at least 97%) sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 36.

[0025] SEQ ID NOs: 1 to 36 and the names of the virus strains are shown below. - An example of an HA stem region of H1 (A / Narita / 1 / 2009 (H1N1pmd09)) YHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEID (SEQ ID NO: 1) - An example of an HA stem region of H2 (A / Korea / 426 / 1968 (H2N2)) YHHSNDQGSGYAADKESTQKAFNGITNKVNSVIEKMNTQFEAVGKEFSNLEKRLENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRMQLRDNVKELGNGCFEFYHKCDNECMDSVKNGTYDYPKYEEESKLNRNEIK (SEQ ID NO: 2) Example of the HA stem region of H3 (A / X-31 (H3N2)) FRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEWKTNEKFHQIEKEFSEVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENAEDMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIK (SEQ ID NO: 3) Example of the HA stem region of H4 (A / Duck / Alberta / 28 / 1976 (H4N6)) FRHQNAEGTGTAADLKSTQAAIDQINGKLNRLIEKTNEKYHQIEKEFEQVEGRIQDLEKYVEDTKIDLWSYNAEFLVALENQHTIDVTDSEMNKLFERVRRQLRENAEDKGNGCFEIFHQCDNNCIESIRNGTYDHDIYRDEAINNRFQIQ (SEQ ID NO: 4) Example of the HA stem region of H5 (A / NIBRG-14 (H5N1)) YHHSNEQGSGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESVRNGTYDYPQYSEEARLKREEIS (SEQ ID NO: 5)An example of the HA stem region of H6 (A / duck / Fujia5498 / 2006(H6N6)) YHHENSQGSGYAADRESTQKAIDGITTKVNSIIDKMNTQFEAVGHEFSNLERRIDNLNKRMEDGFLDVWTYNAELLVLLENERTLDLHDANVKNLHERVKSQLRDNANDLGNGCFEFWHKCDNECMESVKNGTYNYPKYQAESRLNKQKIE (SEQ ID NO: 6) An example of the HA stem region of H7 (A / Anhui / 1 / 2013(H7N9)) FRHQNAQGEGTAADYKSTQSAIDQITGKLNRLIEKTNQQFELIDNEFNEVEKQIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENAEEDGTGCFEIFHKCDDDDCMASIRNNTYDHSKYREEAMQNRIQID (SEQ ID NO: 7) Example of the HA stem region of H8 (A / Shelduck / Ukraine / Arabatska Strilka-1-10-10 / 2010 (H8N4)) FHHSNSEGTGMAADQKSTQEAIDKITNKVNNIVDKMNREFEVVNHEFSEVEKRINMINGKIDDQIEDLWAYNAELLVLLENQKTLDEHDSNVKNLFDEVRRRRLSANAIDTGNGCFDILHKCDNECMETIKNGTYNHKKEYEEEAKLERSKIN (SEQ ID NO: 8) Example of the HA stem region of H9 (A / wild bird / Anhui / S93 / 2014(H9N2)) FQHSNDQGVGMAADRESTQEAVDKITSKVNNIIDKMNKQYEIIDHEFSEIEARLNMINNKIDDQIQDIWAYNAELLVLLENQKTLDEHDANVNNLYNKVKRALGSNAREDGNGCFELYHKCDDQCMETIRNGTYDRQKYQEESKLERQKIE (SEQ ID NO: 9) Example of the HA stem region of H10 (A / mandarin duck / Singapore / 805_F-72_7 / 1993(H10N5))FRHQNAQGTGQAADYKSTQAAIDQITGKLNRLIEKTNTEFESIESEFSEIEHQIGNIINWTKDSITDIWTYQAELLVAMENQHTIDMADSEMLNLYERVRKQLRQNAEEDGKGCFEIYHACDDSCMESIRNNTYDHSQYREEALLNRLNIN (SEQ ID NO: 10) Example of the HA stem region of H11 (A / blue-winged teal / Ohio / 12OS2099 / 2012(H11)) FQHRNEEGTGIAADKESTQKAIDQITSKVNNIVDRMNTNFESAQHEFSEIEERINQLSKHVDDSVIDIWSYNAQLLVLLENEKTLDLHDSNVRNLHERVRRMLKDNAKDEGNGCFTFYHKCDNECIEKVRNGTYDHKEFEEESKLNRQEIE (SEQ ID NO: 11) Example of the HA stem region of H12 (A / mallard / Interior Alaska / 9BM1907R1 / 2009(H12)) FQHQNAEGTGIAADRDSTQKAIDNMQNKLNNVIDKMNKQFEVVNHEFSEVESRINMINSKIDDQITDIWAYNAELLVLLENQKTLDEHDANVRNLHDRVRRVLRENAIDTGDGCFEILHKCDNNCMDTIRNGTYNHKKEYEEESKIERQKIN (SEQ ID NO: 12) Example of the HA stem region of H13 (A / black-headed gull / Netherlands / 7 / 2009(H13N2)) FQHQNEQGTGIAADKESTQKAIDQITTKINNIIDKMNGNYDSIRGEFNQVEKRINMLADRIDDAVTDIWSYNAKLLVLLENDKTLDMHDANVRNLHEQVRRELKDNAIDEGNGCFELLHKCNDSCMETIRNGTYDHTEYAEESKLKRQEIN (SEQ ID NO: 13) Example of the HA stem region of H14 (A / blue-winged teal / Guatemala / CIP049H105-15 / 2011(H14N3))FRHQNAEGTGTAADLKSTQAAIDQINGKLNRLVEKTNEKYHQIEKEFEQVEGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDVTDSEMNKLFERVRRQLRENAEDQGNGCFEIFHQCDNNCIESIRNGTYDHNIYRDEAINNRIKIN (SEQ ID NO: 14) Example of the HA stem region of H15 (A / mallard / Novomychalivka / 2-23-12 / 2010(H15N7)) FRHQNAQGQGTAADYKSTQAAIDQITGKLNRLIEKTNQQFELIDNEFTEVEQQIGNVINWTRDSLTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENAEEDGTGCFEIFHRCDDQCMESIRNNTYNHTEYRQESLQNRIMID (SEQ ID NO: 15) Example of the HA stem region of H16 (A / black-headed gull / Netherlands / 26 / 2009(H16N3)) FQHQNEQGTGIAADKASTQKAIDEITTKINNIIEKMNGNYDSIRGEFNQVEKRINMLADRVDDAVTDVWSYNAKLLVLLENGRTLDLHDANVRNLHDQVKRALKNNAIDEGDGCFNLLHKCNDSCMETIRNGTYNHEDYQEESQLKRQEIE (SEQ ID NO: 16) Example of the HA stem region of H17 (A / little yellow-shouldered bat / Guatemala / 060 / 2010 (H17N10)) YHHENQEGSGYAADKEATQKAVDGITNKVNSIIDKMNSQFESNIKEFNRLELRIQHLSDRVDDALLDIWSYNTELLVLLENERTLDFHDANVKNLFEKVKAQLKDNAIDEGNGCFLLLHKCNNSCMDDIKNGTYKYMDYREESHIEKQKID (SEQ ID NO: 17) Example of the HA stem region of H18 (A / flat-faced Bat / peru / 033 / 2010 (H18N11))YHHQNSEGSGYAADKEATQKAVDAITTKVNNIIDKMNTQFESTAKEFNKIEMRIKHLSDRVDDDGFLDVWSYNAELLVLLENERTLDFHDANVNNLYQKVKVQLKDNAIDMGNGCFKILHKCNNTCMDDIKNGTYNYYEYRKESHLEKQKID (SEQ ID NO: 18) An example of the LAH region of H1 RIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNA (SEQ ID NO: 19) An example of the LAH region of H2 RLENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRMQLRDNV (SEQ ID NO: 20) An example of the LAH region of H3 RIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQLRENA (SEQ ID NO: 21) An example of the LAH region of H4 RIQDLEKYVEDTKIDLWSYNAEFLVALENQHTIDVTDSEMNKLFERVRRQLRENA (SEQ ID NO: 22) An example of the LAH region of H5 RIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLR DNA (SEQ ID NO: 23) An example of the LAH region of H6 RIDNLNKRMEDGFLDVWTYNAELLVLLENERTLDLHDANVKNLHERVKSQLR DNA (SEQ ID NO: 24) An example of the LAH region of H7 QIGNVINWTRDSITEVWSYNAELLVAMENQHTIDLADSEMDKLYERVKRQLRENA (SEQ ID NO: 25) An example of the LAH region of H8 RINMINGKIDDQIEDLWAYNAELLVLLENQKTLDEHDSNVKNLFDEVRRRLSANA (SEQ ID NO: 26) An example of the LAH region of H9 RLNMINNKIDDQIQDIWAYNAELLVLLENQKTLDEHDANVNNLYNKVKRALGSNA (SEQ ID NO: 27) An example of the LAH region of H10 QIGNIINWTKDSITDIWTYQAELLVAMENQHTIDMADSEMLNLYERVRKQLRQNA (SEQ ID NO: 28) An example of the LAH region of H11 RINQLSKHVDDSVIDIWSYNAQLLVLLENEKTLDLHDSNVRNLHERVRRMLKDNA (SEQ ID NO: 29)An example of an LAH region of H12: RINMINSKIDDQITDIWAYNAELLVLLENQKTLDEHDANVRNLHDRVRRVLRENA (SEQ ID NO: 30) An example of an LAH region of H13: RINMLADRIDDAVTDIWSYNAKLLVLLENDKTLDMHDANVRNLHEQVRRELKDNA (SEQ ID NO: 31) An example of an LAH region of H14: RIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDVTDSEMNKLFERVRRQLRENA (SEQ ID NO: 32) An example of an LAH region of H15: QIGNVINWTRDSLTEIWSYNAELLVAMENQHTIDLADSEMNKLYERVRRQLRENA (SEQ ID NO: 33) An example of the LAH region of H16 RINMLADRVDDAVTDVWSYNAKLLVLLENGRTLDLHDANVRNLHDQVKRALKNNA (SEQ ID NO: 34) An example of the LAH region of H17 RIQHLSDRVDDALLDIWSYNTELLVLLENERTLDFHDANVKNLFEKVKAQLKDNA (SEQ ID NO: 35) An example of the LAH region of H18 RIKHLSDRVDDGFLDVWSYNAELLVLLENERTLDFHDANVNNLYQKVKVQLKDNA (SEQ ID NO: 36)

[0026] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against influenza A virus infection. As used herein, the ability to protect against influenza virus infection includes, for example, the ability to prevent influenza virus infection in a subject, the ability to increase the survival rate of a subject infected with influenza virus, and / or the ability to alleviate disease symptoms in a subject infected with influenza virus. As used herein, "having the ability to protect against influenza virus infection" means having the ability to protect against at least one influenza virus strain. Whether the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against infection can be confirmed by a commonly used method. For example, similar to the method described in the Examples of the present application, mice previously administered with the monoclonal antibody / antibody fragment of the present disclosure are challenged with influenza virus and their subsequent weight changes and survival rates are examined. If there is less weight loss and a higher survival rate than a negative control, the antibody is considered to have the ability to protect against infection.

[0027] In one aspect, the present disclosure provides a pharmaceutical composition (hereinafter sometimes referred to as the pharmaceutical composition of the present disclosure) containing the monoclonal antibody / antibody fragment of the present disclosure. Because the monoclonal antibody or antibody fragment thereof of the present disclosure may be useful for treating or preventing influenza A infection, the monoclonal antibody or antibody fragment thereof of the present disclosure may be an active ingredient of a pharmaceutical composition for treating or preventing influenza A infection. In one embodiment, the pharmaceutical composition of the present disclosure is used to treat or prevent influenza A virus infection. Prevention of influenza A infection includes preventing the onset of the disease by inhibiting the adsorption of influenza A virus to cell surfaces, inhibiting its entry into cells, and damaging and removing virus-infected cells. "Treatment of influenza A infection" includes curing or alleviating symptoms caused by influenza A infection.

[0028] In one aspect, the present disclosure provides a monoclonal antibody or antibody fragment thereof of the present disclosure for use in treating or preventing influenza A virus infection.

[0029] In one aspect, the present disclosure provides a method of treating or preventing influenza A virus infection, comprising administering to a subject a monoclonal antibody or antibody fragment thereof of the present disclosure.

[0030] In one aspect, the present disclosure provides the use of a monoclonal antibody or antibody fragment thereof of the present disclosure in the manufacture of a medicament for treating or preventing influenza A virus infection.

[0031] In one aspect, the present disclosure provides a use of a monoclonal antibody or antibody fragment thereof of the present disclosure for treating or preventing influenza A virus infection.

[0032] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) derived from two or more different influenza A virus strains. The term "cross-reactivity" is sometimes used herein, and as used herein, "cross-reactivity" means binding to the HA stem region (or LAH region) derived from two or more different influenza A virus strains. In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against infection with two or more different influenza A virus strains. In one embodiment, the pharmaceutical composition of the present disclosure is used for treating or preventing infection with two or more different influenza A virus strains. The two or more different influenza virus strains may be two or more influenza virus strains belonging to the same HA subtype, or two or more influenza virus strains belonging to different HA subtypes.

[0033] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) from two or more different influenza virus strains belonging to the same HA subtype. In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against infection with two or more different influenza virus strains belonging to the same HA subtype. In one embodiment, the pharmaceutical composition of the present disclosure can be used to treat or prevent infection with two or more different influenza virus strains belonging to the same HA subtype. For example, the monoclonal antibody / antibody fragment of the present disclosure that binds to the HA stem region (SEQ ID NO: 3) or LAH region (SEQ ID NO: 21) of A / X-31(H3N2) can be used to bind to other virus strains of the H3 subtype, such as A / Victoria / 361 / 2011 (H3N2), A / Singapore / INFIMH-16-0019 / 2016 (H3N2), A / Kansas / 14 / 2017 (H3N2), A / Aichi / 2 / 1968 (H3N2), in addition to A / X-31(H3N2). (H3N2), A / Fujian / 411 / 02(H3N2), A / Guizhou / 54 / 89(H3N2), A / OMS / 5389 / 88(H3N2), A / Beijing / 32 / 92(H3N2), A / Englan d / 427 / 88(H3N2), A / Johannesburg / 33 / 94(H3N2), A / Leningrad / 360 / 86(H3N2), A / Mississippi / 1 / 85(H3N2), A / Philipp and A / C19 / 100 / 102 / 102 (H3N2), A / C19 ...For example, the monoclonal antibody / antibody fragment of the present disclosure that binds to the HA stem region (SEQ ID NO: 1) or LAH region (SEQ ID NO: 19) of A / Narita / 1 / 2009 (H1N1pdm09) can be used to bind to other virus strains of the H1 subtype in addition to A / Narita / 1 / 2009 (H1N1pdm09), such as A / Puerto Rico / 8 / 34(H1N1), A / Michigan / 45 / 2015 (H1N1pdm09), A / Brisbane / 02 / 2018 (H1N1pdm09), A / Beijing / 262 / 95(H1N1), A / Brazil / 11 / 78(H1N1), A / Chile / 1 / 83(H1N1), A / New The antibody may have binding activity and / or protective ability against viruses such as Jersey / 8 / 76 (H1N1), A / Taiwan / 1 / 86 (H1N1), A / Yamagata / 32 / 89 (H1N1), A / New Caledonia / 20 / 99 (H1N1), A / Solomon Islands / 3 / 2006 (H1N1), A / Brisbane / 59 / 2007 (H1N1), or A / Mexico / 4108 / 2009 (H1N1).

[0034] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region of two or more different influenza A virus HA subtypes. As used herein, "the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region of two or more different influenza A virus HA subtypes" means that the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) derived from at least one influenza A virus strain of one HA subtype, and binds to the HA stem region (or LAH region) derived from at least one influenza A virus strain of another HA subtype. In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against infection with two or more different influenza A virus HA subtypes. The phrase "the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against infection with two or more different influenza A virus HA subtypes" means that the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against infection with at least one influenza virus strain of one HA subtype and at least one influenza virus strain of another HA subtype. In one embodiment, the pharmaceutical composition of the present disclosure is used for treating or preventing infection with two or more different influenza A virus HA subtypes.

[0035] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) of two or more different influenza A virus HA subtypes belonging to phylogenetic group 1. As used herein, "the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) of two or more different influenza A virus HA subtypes belonging to phylogenetic group 1" means that the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) derived from at least one influenza virus strain of a certain influenza A virus HA subtype belonging to phylogenetic group 1, and binds to the HA stem region (or LAH region) derived from at least one influenza virus strain of another influenza A virus HA subtype belonging to phylogenetic group 1. In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against infection with two or more different influenza A virus HA subtypes belonging to phylogenetic group 1. As used herein, the phrase "the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against two or more different influenza A virus HA subtypes belonging to phylogenetic group 1" means that the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against at least one influenza virus strain of a certain influenza A virus HA subtype belonging to phylogenetic group 1, and is also capable of protecting against at least one influenza virus strain of another influenza A virus HA subtype belonging to phylogenetic group 1. For example, a monoclonal antibody or antibody fragment thereof that binds to the H1 LAH region of the present disclosure may also be capable of binding to and protecting against influenza viruses of the H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and / or H18 subtypes that also belong to phylogenetic group 1. The monoclonal antibody or antibody fragment thereof that binds to the LAH region of H1 of the present disclosure preferably also has the ability to bind to and / or protect against infection with influenza viruses of the H5 subtype that belong to the same phylogenetic group 1 of the A virus type.Specific examples of the monoclonal antibody or antibody fragment thereof of the present disclosure that binds to the LAH region of H1 and the LAH region of H5 include clone 3, clone 4, clone 6, clone 7, and clone 8 described in the Examples of the present application. In one embodiment, the pharmaceutical composition of the present disclosure is used to treat or prevent infection with two or more different influenza A virus HA subtypes belonging to phylogenetic group 1.

[0036] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) of two or more different influenza A virus HA subtypes belonging to phylogenetic group 2. As used herein, "the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) of two or more different influenza A virus HA subtypes belonging to phylogenetic group 2" means that the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) derived from at least one influenza virus strain of a certain influenza A virus HA subtype belonging to phylogenetic group 2, and binds to the HA stem region (or LAH region) derived from at least one influenza virus strain of another influenza A virus HA subtype belonging to phylogenetic group 2. In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against infection with two or more different influenza A virus HA subtypes belonging to phylogenetic group 2. As used herein, the phrase "the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against two or more different influenza A virus HA subtypes belonging to phylogenetic group 2" means that the monoclonal antibody / antibody fragment of the present disclosure is capable of protecting against at least one influenza virus strain of a certain influenza A virus HA subtype belonging to phylogenetic group 2, and is also capable of protecting against at least one influenza virus strain of another influenza A virus HA subtype belonging to phylogenetic group 2. For example, an H3 LAH region-binding monoclonal antibody or antibody fragment thereof of the present disclosure may also be capable of binding to and protecting against influenza viruses of the H4, H7, H10, H14, and / or H15 subtypes, which also belong to phylogenetic group 2 of influenza A. An H3 LAH region-binding monoclonal antibody or antibody fragment thereof of the present disclosure preferably also has the ability to bind to and / or protect against influenza viruses of the H7 subtype, which also belong to phylogenetic group 2 of influenza A.Specific examples of the monoclonal antibody or antibody fragment thereof of the present disclosure that binds to the LAH region of H3 and the LAH region of H7 include clone 1, clone 2, clone 5, clone 6, and clone 7 described in the Examples of the present application. In one embodiment, the pharmaceutical composition of the present disclosure is used to treat or prevent infection with two or more different influenza A virus HA subtypes belonging to phylogenetic group 2.

[0037] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) of influenza A virus HA subtypes belonging to phylogenetic group 1, and binds to the HA stem region (or LAH region) of influenza A virus HA subtypes belonging to phylogenetic group 2.

[0038] As used herein, the phrase "a monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) of an influenza A virus HA subtype belonging to phylogenetic group 1" means that the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) derived from at least one influenza virus strain of an influenza A virus HA subtype belonging to phylogenetic group 1. As used herein, the phrase "a monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) of an influenza A virus HA subtype belonging to phylogenetic group 2" means that the monoclonal antibody / antibody fragment of the present disclosure binds to the HA stem region (or LAH region) derived from at least one influenza virus strain of an influenza A virus HA subtype belonging to phylogenetic group 2.

[0039] In one embodiment, the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against influenza A virus HA subtypes belonging to phylogenetic group 1, and has the ability to protect against influenza A virus HA subtypes belonging to phylogenetic group 2.

[0040] As used herein, the phrase "the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against infection with influenza A virus HA subtypes belonging to phylogenetic group 1" means that the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against infection with at least one influenza virus strain of influenza A virus HA subtypes belonging to phylogenetic group 1. As used herein, the phrase "the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against infection with influenza A virus HA subtypes belonging to phylogenetic group 2" means that the monoclonal antibody / antibody fragment of the present disclosure has the ability to protect against infection with at least one influenza virus strain of influenza A virus HA subtypes belonging to phylogenetic group 2.

[0041] For example, a monoclonal antibody or antibody fragment binding to the H3 LAH region of the present disclosure may have binding activity and protective ability against influenza viruses of subtypes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and / or H18 of phylogenetic group 1, in addition to influenza viruses of subtypes H3, H4, H7, H10, H14, and / or H15 of phylogenetic group 2. Specific examples include clone 6 and clone 7 described in the Examples. A monoclonal antibody or antibody fragment that binds to the HA stem region (or LAH region) of influenza A virus HA subtypes belonging to phylogenetic group 1 and to the HA stem region (or LAH region) of influenza A virus HA subtypes belonging to phylogenetic group 2 may have cross-reactivity with all subtypes that are infectious to humans (specifically, H1, H3, H5, H7, and H9), and therefore may be effective as a therapeutic agent in the event of a pandemic.

[0042] In one embodiment, the pharmaceutical compositions of the present disclosure are used to treat or prevent infection with influenza A virus HA subtypes belonging to phylogenetic group 1 and influenza A virus HA subtypes belonging to phylogenetic group 2.

[0043] At least HA subtypes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18 are known to belong to phylogenetic group 1, and at least HA subtypes H3, H4, H7, H10, H14, and H15 belong to phylogenetic group 2. With further discoveries, additional subtypes may be added to these groups.

[0044] As used herein, the term "antibody" refers to an immunoglobulin molecule that comprises two light chains and two heavy chains and binds to an antigen, and is used to include mouse antibodies, chimeric antibodies (e.g., mouse-human chimeric antibodies), humanized antibodies, fully human antibodies (also simply referred to as human antibodies), multispecific antibodies (e.g., bispecific antibodies), and the like. As used herein, the term "monoclonal antibody" refers to a population of antibodies consisting essentially of one type of molecular species, unless otherwise specified. Monoclonal antibodies can be produced by methods commonly used in the art. In one embodiment, the monoclonal antibody of the present disclosure is an isolated monoclonal antibody.

[0045] Immunoglobulin classes of antibodies include IgG, IgM, IgA, IgD, and IgE. The basic structure of immunoglobulin molecules is common to all classes and consists of a heavy chain with a molecular weight of 50,000-70,000 and a light chain with a molecular weight of 20,000-30,000. Heavy chains are typically polypeptides containing approximately 440 amino acids, and each class has a characteristic structure. The heavy chains corresponding to IgG, IgM, IgA, IgD, and IgE are called γ chains, μ chains, α chains, δ chains, and ε chains, respectively. Immunoglobulin classes are further divided into subclasses. For example, IgG has subclasses IgG1, IgG2, IgG3, and IgG4, and these heavy chains are called γ1, γ2, γ3, and γ4, respectively. The immunoglobulin class of the monoclonal antibody of the present disclosure is not particularly limited. In one embodiment, the monoclonal antibody of the present disclosure is an IgG. Light chains are polypeptides typically containing approximately 220 amino acids, and L-type and K-type light chains are known, referred to as λ chains and κ chains, respectively. The light chains of the monoclonal antibodies of the present disclosure may be λ chains or κ chains. The basic structure of an immunoglobulin molecule comprises two heavy chains and two light chains bound by disulfide bonds (S-S bonds) and non-covalent bonds, and has a molecular weight of 150,000-190,000. In the monoclonal antibodies of the present disclosure, the two heavy chains in one immunoglobulin molecule may be the same or different. The two light chains in one immunoglobulin molecule may be the same or different.

[0046] Heavy chains have four (γ chain, α chain, δ chain) or five (μ chain, ε chain) intrachain S-S bonds, while light chains have two intrachain S-S bonds. In both heavy and light chains, one constant region loop is formed every 100-110 amino acid residues. The three-dimensional structure formed by this constant region loop is similar between the structural units connected by each constant region loop, and this structural unit is called a domain. In both heavy and light chains, the domain located at the N-terminus has a variable region (V region) whose amino acid sequence is not constant even in antibodies of the same class (subclass) from the same animal. The heavy chain variable region is V H , the light chain variable region is V LThe amino acid sequence C-terminal to the variable region is almost constant for each class or subclass, and is called the constant region (C region). Each domain of the heavy chain constant region is C H 1. C H 2, and C H 3. The light chain constant region domain is C L It is sometimes expressed as:

[0047] The antigen-binding site of an antibody is the heavy chain variable region (V H ) and the light chain variable region (V L The specificity of binding is determined by the amino acid sequence of this site. The variability of the heavy and light chain variable regions is known to be provided by three small hypervariable regions present in each chain, and these regions are called complementarity-determining regions (CDRs). Several numbering systems for determining CDRs are commonly used, including Kabat, Chothia, AbM, and IMGT (Martin et al. (1989) Proc. Natl. Acad. Sci. USA 86: 9268-9272; Martin et al. (1991) Methods Enzymol. 203: 121-153; Pedersen et al. (1992) Immunomethods 1: 126; Rees et al. (1996) In Sternberg MJE (ed.), Protein Structure Prediction, Oxford University Press, Oxford, pp. 141-172; Lefranc et al. (2003) Dev Comp Immunol. 27: 55-77). Additionally, online tools such as IMGT / V-QUEST (http: / / www.imgt.org / ) are used to identify CDRs. In this disclosure, unless otherwise specified, the CDRs of the heavy and light chain variable regions are determined by IMGT.

[0048] The portions of the variable region excluding the CDRs are called framework regions (FRs), and their amino acid sequences are relatively constant. Therefore, by CDR grafting, it is possible to transfer the binding specificity of one antibody to another. The framework regions form a β-sheet structure, and the CDRs can form loops that connect the β-sheet structure. The CDRs of the heavy and light chains are held in their three-dimensional structure by the framework regions, forming the antigen-binding site.

[0049] Biological activities such as binding to complement or various cells depend on the structure of the constant region of each immunoglobulin class. The constant region of the monoclonal antibody of the present disclosure may be modified to regulate antibody-dependent cellular cytotoxicity (ADCC) activity, complement-dependent cytotoxicity (CDC) activity, pharmacokinetics, etc. Modifications include modifications of the amino acid sequence or sugar chain.

[0050] In the present disclosure, a human antibody is an antibody whose entire sequence is human; a humanized antibody is an antibody whose sequences other than the CDRs are human; a chimeric antibody is an antibody whose variable region is non-human and whose constant region is human; and a murine antibody is an antibody whose entire sequence is murine. Humanized and chimeric antibodies can be produced by genetic engineering using standard methods. Human antibodies can be produced using human-human (or human-mouse) hybridomas, phage display methods, human antibody-producing animals (e.g., mice), or genetic engineering methods using antibody genes prepared from human B cells. Murine antibodies can be produced by cell fusion or genetic engineering methods using lymphocytes from immunized animals. Antibody fragments can be produced by genetic engineering or can be obtained from libraries such as Fab expression libraries.

[0051] The antibody fragment of the present disclosure refers to a molecule that contains a portion of the antibody molecule of the monoclonal antibody of the present disclosure and has antigen-binding ability. For example, a single-chain antibody (single-chain FV, scFV), F(ab') 2Examples of antibody fragments include scFv, Fab', Fab, Fv, and single-domain antibodies. The antibody fragments can be produced by conventional methods in the art. For details about scFv, see, for example, Ahmad, ZA et al. scFv antibody: principles and clinical application. Clin. Dev. Immunol. 2012, 980250 (2012). Single-domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain or all or part of the light chain variable domain of an antibody. For details about single-domain antibodies, see, for example, Ward et al., 1989 Nature 341:544-546. In one embodiment, the antibody fragment of the present disclosure is an isolated antibody fragment.

[0052] Isolated nucleic acids encoding the monoclonal antibodies or antibody fragments thereof of the present disclosure are also included in one aspect of the invention.

[0053] In this disclosure, the term "isolated" means altered from the natural state or partially or completely separated from the natural state. For example, an isolated nucleic acid or protein can exist in a substantially purified form or can exist in a non-native environment, such as a host cell. Also, for example, an isolated antibody can mean that it is substantially free of other antibodies having different antigenic specificities. Furthermore, an isolated antibody can mean that it is substantially free of other cellular material and / or chemicals.

[0054] In the present disclosure, "at least one (at least one type)" means one (one type) or more, and includes, within the scope of the present disclosure, for example, at least two (at least two types), at least three (at least three types), at least four (at least four types), at least five (at least five types), at least six (at least six types), at least seven (at least seven types), at least eight (at least eight types), at least nine (at least nine types), and at least ten (at least ten types). Furthermore, "at least one (at least one type)" includes, within the scope of the present disclosure, for example, 1 to 18, 1 to 10, 1 to 5, or 1 to 3 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18), but may also mean a larger number.

[0055] The present inventors obtained LAH region-binding monoclonal antibodies (clones 1 to 8), analyzed the amino acid sequence of each antibody, and determined the variable regions and CDRs of each antibody. Tables 1 to 7 in the Examples section show the amino acid sequences of the variable regions and CDRs of clones 1 to 8.

[0056] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a)-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 47 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 48 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 49 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 50 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 52 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a)-2 a heavy chain variable region comprising: a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 47 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 48 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 49 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 50 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 52 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.

[0057] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a')-1 a heavy chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 47, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 48, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 49, and / or a light chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 50, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 51, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 52; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a')-2 a heavy chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:47, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:48, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:49, and a light chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:50, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:51, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:52;

[0058] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a'')-1 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 53, and / or a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 54. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a'')-2 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 53, and a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 54.

[0059] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 53, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 54. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 53, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 54.

[0060] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a'''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 53 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 54 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (a'''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 53 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 54 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence;

[0061] In one embodiment, the monoclonal antibodies or antibody fragments thereof of (a)-1 and -2, (a')-1 and -2, (a'')-1 and -2, (a''')-1 and -2, and (a'''')-1 and -2 (hereinafter sometimes referred to as clone 2-derived antibodies / antibody fragments) bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21. In one embodiment, the clone 2-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 2-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21 and / or bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 2-derived antibodies / antibody fragments have the ability to protect against influenza A virus subtypes H3 and / or H7. In one embodiment, the clone 2-derived antibody / antibody fragment is used to treat or prevent infection with influenza A virus HA subtypes belonging to phylogenetic group 2 (e.g., two or more different influenza A virus HA subtypes belonging to phylogenetic group 2). In one embodiment, the clone 2-derived antibody / antibody fragment is used to treat or prevent infection with H3 and / or H7 subtypes. In one embodiment, the clone 2-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens derived from influenza A virus HA subtypes belonging to phylogenetic group 2. In one embodiment, the clone 2-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens derived from H3 and / or H7 subtypes.

[0062] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b)-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 55 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 56 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 57 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 58 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 60 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b)-2 a heavy chain variable region comprising: a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 55 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 56 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 57 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 58 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 60 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.

[0063] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b')-1 a heavy chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 55, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 56, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 57, and / or a light chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 58, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 59, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 60; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b')-2 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:55, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:56, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:57, and a light chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:58, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:59, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:60;

[0064] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b'')-1 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 61, and / or a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 62. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b'')-2 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 61, and a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 62.

[0065] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 61, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 62. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 61, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 62.

[0066] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b'''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 61 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 62 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (b'''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 61 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 62 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence;

[0067] In one embodiment, the monoclonal antibodies or antibody fragments thereof of (b)-1 and -2, (b')-1 and -2, (b'')-1 and -2, (b''')-1 and -2, and (b'''')-1 and -2 (hereinafter sometimes referred to as clone 3-derived antibodies / antibody fragments) bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19. In one embodiment, the clone 3-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 3-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19 and also binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 3-derived antibody / antibody fragment has the ability to protect against influenza A virus subtypes H1 and / or H5. In one embodiment, the clone 3-derived antibody / antibody fragment is used to treat or prevent infection with influenza A virus HA subtypes belonging to phylogenetic group 1 (e.g., two or more different influenza A virus HA subtypes belonging to phylogenetic group 1). In one embodiment, the clone 3-derived antibody / antibody fragment is used to treat or prevent infection with H1 and / or H5 subtypes. In one embodiment, the clone 3-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens derived from influenza A virus HA subtypes belonging to phylogenetic group 1. In one embodiment, the clone 3-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens derived from H1 and / or H5 subtypes.

[0068] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c)-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 63 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 64 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 65 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 66 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 68 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c)-2 a heavy chain variable region comprising: a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 63 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 64 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 65 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence. a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 68 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.

[0069] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c')-1 a heavy chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 63, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 64, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 65, and / or a light chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 66, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 67, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 68; (c')-2 A heavy chain variable region comprising: CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 63; CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 64; and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 65; and a light chain variable region comprising: CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 66; CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 67; and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 68.

[0070] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c'')-1 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 69, and / or a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 70. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c'')-2 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 69, and a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 70.

[0071] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 69, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 70. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 69, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 70.

[0072] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c'''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 69 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 70 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (c'''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 69 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 70 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence;

[0073] In one embodiment, the monoclonal antibodies or antibody fragments thereof of (c)-1 and -2, (c')-1 and -2, (c'')-1 and -2, (c''')-1 and -2, and (c'''')-1 and -2 (hereinafter sometimes referred to as clone 4-derived antibody / antibody fragment or clone 8-derived antibody / antibody fragment) bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19. In one embodiment, the clone 4-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 4-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19 and also binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 4-derived antibody / antibody fragment has the ability to protect against influenza A virus subtypes H1 and / or H5. In one embodiment, the clone 4-derived antibody / antibody fragment is used to treat or prevent infection with influenza A virus HA subtypes belonging to phylogenetic group 1 (e.g., two or more different influenza A virus HA subtypes belonging to phylogenetic group 1). In one embodiment, the clone 4-derived antibody / antibody fragment is used to treat or prevent infection with H1 and / or H5 subtypes. In one embodiment, the clone 4-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from influenza A virus HA subtypes belonging to phylogenetic group 1. In one embodiment, the clone 4-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from H1 and / or H5 subtypes.

[0074] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d)-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 71 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 72 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 73 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and / or a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 74 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 76 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence.(d)-2 A heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 71 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in the amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 72 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in the amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in the amino acid sequence; and a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in the amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in the amino acid sequence; a light chain variable region comprising a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 76, or said amino acid sequence with one or two amino acid residues independently substituted, deleted, added, or inserted.

[0075] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d')-1 a heavy chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 71, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 72, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 73, and / or a light chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 74, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 75, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 76; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d')-2 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 71, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 72, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 73, and a light chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 74, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 75, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 76;

[0076] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d'')-1 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 77, and / or a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 78. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d'')-2 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 77, and a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 78.

[0077] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 77, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 78. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 77, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 78.

[0078] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d'''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 77 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 78 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (d'''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 77 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 78 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence.

[0079] In one embodiment, the monoclonal antibodies or antibody fragments thereof of (d)-1 and -2, (d')-1 and -2, (d'')-1 and -2, (d''')-1 and -2, and (d'''')-1 and -2 (hereinafter sometimes referred to as clone 5-derived antibodies / antibody fragments) bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21. In one embodiment, the clone 5-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 5-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21, and also binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 5-derived antibody / antibody fragment has the ability to protect against influenza A virus subtypes H3 and / or H7. In one embodiment, the clone 5-derived antibody / antibody fragment is used to treat or prevent infection with influenza A virus HA subtypes belonging to phylogenetic group 2 (e.g., two or more different influenza A virus HA subtypes belonging to phylogenetic group 2). In one embodiment, the clone 5-derived antibody / antibody fragment is used to treat or prevent infection with H3 and / or H7 subtypes. In one embodiment, the clone 5-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from influenza A virus HA subtypes belonging to phylogenetic group 2. In one embodiment, the clone 5-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from H3 and / or H7 subtypes.

[0080] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e)-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 79 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 80 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 81 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and / or a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 82 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 84 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e)-2 a heavy chain variable region comprising: a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 79 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 80 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 81 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 82 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence. a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 84 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.

[0081] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e')-1 a heavy chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:79, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:80, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:81, and / or a light chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:82, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:83, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:84; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e')-2 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:79, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:80, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:81, and a light chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO:82, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO:83, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO:84;

[0082] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e'')-1 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 85, and / or a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 86. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e'')-2 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 85, and a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 86.

[0083] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 85, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 86. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 85, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 86.

[0084] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e'''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 85 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 86 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (e'''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 85 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 86 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence;

[0085] In one embodiment, the monoclonal antibodies or antibody fragments thereof of (e)-1 and -2, (e')-1 and -2, (e'')-1 and -2, (e''')-1 and -2, and (e'''')-1 and -2 (hereinafter sometimes referred to as clone 6-derived antibodies / antibody fragments) bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21. In one embodiment, the clone 6-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 6-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21, and also bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 6-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19. In one embodiment, the clone 6-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 6-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19, and also binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 6-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21, binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25, binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19, and binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 6-derived antibody / antibody fragment has the ability to protect against infection with at least one subtype (e.g., H3 and / or H1 subtype) selected from the group consisting of influenza A virus subtypes H3, H7, H1, and H5.In one embodiment, the clone 6-derived antibody / antibody fragment is used to treat or prevent infections caused by influenza A virus HA subtypes belonging to phylogenetic group 1 and / or 2 (e.g., two or more different influenza A virus HA subtypes belonging to phylogenetic group 1 and / or two or more different influenza A virus HA subtypes belonging to phylogenetic group 2). In one embodiment, the clone 6-derived antibody / antibody fragment is used to treat or prevent infections caused by H1, H3, H5 and / or H7 subtypes. In one embodiment, the clone 6-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from influenza A virus HA subtypes belonging to phylogenetic group 1 and / or 2. In one embodiment, the clone 6-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from H1, H3, H5 and / or H7 subtypes. In one embodiment, the clone 6-derived antibody / antibody fragment has the ability to protect against infection with at least one subtype selected from the group consisting of influenza A virus subtypes H1, H2, H5, H6, H8, H9, H11, H16, H17, H18, H3, H4, H7, H10, H14, and H15 (e.g., H1, H2, H5, H6, H17, H18, H3, H4, H7, H10, H14, and H15 subtypes). In one embodiment, the Clone 6-derived antibody / antibody fragment is used to treat or prevent infection with at least one subtype selected from the group consisting of influenza A virus subtypes H1, H2, H5, H6, H8, H9, H11, H16, H17, H18, H3, H4, H7, H10, H14, and H15 (e.g., H1, H2, H5, H6, H17, H18, H3, H4, H7, H10, H14, and H15 subtypes).In one embodiment, the clone 6-derived antibody / antibody fragment is used to detect or quantify fusogenic influenza HA antigen from at least one subtype selected from the group consisting of H1, H2, H5, H6, H8, H9, H11, H16, H17, H18, H3, H4, H7, H10, H14, and H15 subtypes (e.g., H1, H2, H5, H6, H17, H18, H3, H4, H7, H10, H14, and H15 subtypes).

[0086] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f)-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 87 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 88 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 89 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and / or a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 90 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 91 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 92 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f)-2 a heavy chain variable region comprising: a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 87 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 88 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 89 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 90 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 91 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 92 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.

[0087] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f')-1 a heavy chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 87, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 88, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 89, and / or a light chain variable region comprising CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 90, CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 91, and CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 92; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f')-2 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 87, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 88, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 89, and a light chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 90, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 91, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 92;

[0088] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f'')-1 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 93, and / or a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 94. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f'')-2 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 93, and a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 94.

[0089] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 93, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 94. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 93, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 94.

[0090] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f'''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 93 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 94 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (f'''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 93 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 94 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence;

[0091] In one embodiment, the monoclonal antibodies or antibody fragments thereof of (f)-1 and -2, (f')-1 and -2, (f'')-1 and -2, (f''')-1 and -2, and (f'''')-1 and -2 (hereinafter sometimes referred to as clone 7-derived antibodies / antibody fragments) bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21. In one embodiment, the clone 7-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 7-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21, and also binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 7-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19. In one embodiment, the clone 7-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 7-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19, and also binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 7-derived antibody / antibody fragment binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21, binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25, binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 19, and binds to a peptide consisting of the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 23. In one embodiment, the clone 7-derived antibody / antibody fragment has the ability to protect against infection with at least one subtype (e.g., H3 and / or H1 subtype) selected from the group consisting of influenza A virus subtypes H3, H7, H1, and H5.In one embodiment, the clone 7-derived antibody / antibody fragment is used to treat or prevent infections caused by influenza A virus HA subtypes belonging to phylogenetic group 1 and / or 2 (e.g., two or more different influenza A virus HA subtypes belonging to phylogenetic group 1 and / or two or more different influenza A virus HA subtypes belonging to phylogenetic group 2). In one embodiment, the clone 7-derived antibody / antibody fragment is used to treat or prevent infections caused by H1, H3, H5 and / or H7 subtypes. In one embodiment, the clone 7-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from influenza A virus HA subtypes belonging to phylogenetic group 1 and / or 2. In one embodiment, the clone 7-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from H1, H3, H5 and / or H7 subtypes. In one embodiment, the clone 7-derived antibody / antibody fragment has the ability to protect against infection with at least one subtype selected from the group consisting of influenza A virus subtypes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18, H3, H4, H7, H10, H14, and H15 (e.g., H1, H2, H5, H6, H8, H9, H12, H13, H16, H17, H18, H3, H4, H7, H10, H14, and H15). In one embodiment, the clone 7-derived antibody / antibody fragment is used to treat or prevent infection with at least one subtype selected from the group consisting of influenza A virus subtypes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18, H3, H4, H7, H10, H14, and H15 (e.g., H1, H2, H5, H6, H8, H9, H12, H13, H16, H17, H18, H3, H4, H7, H10, H14, and H15 subtypes).In one embodiment, the clone 7-derived antibody / antibody fragment is used to detect or quantify fusogenic influenza HA antigens from at least one subtype selected from the group consisting of H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18, H3, H4, H7, H10, H14, and H15 subtypes (e.g., H1, H2, H5, H6, H8, H9, H12, H13, H16, H17, H18, H3, H4, H7, H10, H14, and H15 subtypes).

[0092] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g)-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 39 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 40 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 41 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, and / or a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 42 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence, a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 43 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 44 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g)-2 a heavy chain variable region comprising: a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 39 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 40 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 41 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; and a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 42 or the amino acid sequence obtained by independently substituting, deleting, adding, or inserting one or two amino acid residues in said amino acid sequence; a light chain variable region comprising a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 43 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 44 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted relative to said amino acid sequence.

[0093] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g')-1 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 39, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 40, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 41, and / or a light chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 42, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 43, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 44; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g')-2 a heavy chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 39, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 40, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 41, and a light chain variable region comprising a CDR1 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 42, a CDR2 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 43, and a CDR3 comprising (or consisting of) the amino acid sequence of SEQ ID NO: 44;

[0094] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g'')-1 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 45, and / or a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 46. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g'')-2 a heavy chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 45, and a light chain variable region comprising (or consisting of) an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 46.

[0095] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 45, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 46. In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 45, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 46.

[0096] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g'''')-1 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 45 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and / or a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 46 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence; In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: (g'''')-2 a heavy chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 45 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence, and a light chain variable region comprising (or consisting of) the amino acid sequence of SEQ ID NO: 46 or an amino acid sequence obtained by independently substituting, deleting, adding, or inserting one to several (e.g., 1 to 10, 1 to 5, 1 to 3) amino acid residues in said amino acid sequence;

[0097] In one embodiment, the monoclonal antibodies or antibody fragments thereof of (g)-1 and -2, (g')-1 and -2, (g'')-1 and -2, (g''')-1 and -2, and (g'''')-1 and -2 (hereinafter sometimes referred to as clone 1-derived antibodies / antibody fragments) bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21. In one embodiment, the clone 1-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 1-derived antibodies / antibody fragments bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 21 and / or bind to a peptide consisting of the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 25. In one embodiment, the clone 1-derived antibodies / antibody fragments have the ability to protect against influenza A virus subtypes H3 and / or H7. In one embodiment, the clone 1-derived antibody / antibody fragment is used to treat or prevent infection with influenza A virus HA subtypes belonging to phylogenetic group 2 (e.g., two or more different influenza A virus HA subtypes belonging to phylogenetic group 2). In one embodiment, the clone 1-derived antibody / antibody fragment is used to treat or prevent infection with H3 and / or H7 subtypes. In one embodiment, the clone 1-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from influenza A virus HA subtypes belonging to phylogenetic group 2. In one embodiment, the clone 1-derived antibody / antibody fragment is used for detection or quantification of membrane-fusogenic influenza HA antigens from H3 and / or H7 subtypes.

[0098] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises a CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87, wherein one or two amino acid residues are independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, 64, 72, 80, and 88, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, 64, 72, 80, and 88 a heavy chain variable region comprising a CDR2 comprising (or consisting of) an amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted, and a CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89, or an amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted, in which one or two amino acid residues have been independently substituted, deleted, added, or inserted, in an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89; and / or CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90 in which one or two amino acid residues are independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, 67, 75, 83, and 91; a light chain variable region comprising: a CDR2 comprising (or consisting of) an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, in which one or two amino acid residues are independently substituted, deleted, added, or inserted, in an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92;In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises a CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 47, 55, 63, 71, 79, and 87, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 47, 55, 63, 71, 79, and 87 in which one or two amino acid residues have been independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 40, 48, 56, 64, 72, 80, and 88, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 40, 48, 56, 64, 72, 80, and 88; a heavy chain variable region comprising: a CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 41, 49, 57, 65, 73, 81, and 89, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 41, 49, 57, 65, 73, 81, and 89, wherein one or two amino acid residues are independently substituted, deleted, added, or inserted;and / or a CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 42, 50, 58, 66, 74, 82, and 90, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 42, 50, 58, 66, 74, 82, and 90 in which one or two amino acid residues are independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 51, 59, 67, 75, 83, and 91; or an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 51, 59, 67, 75, 83, and 91. a light chain variable region comprising a CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 44, 52, 60, 68, 76, 84, and 92, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 44, 52, 60, 68, 76, 84, and 92, wherein one or two amino acid residues have been independently substituted, deleted, added, or inserted (hereinafter sometimes referred to as a clone-derived antibody / antibody fragment);

[0099] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: a heavy chain variable region comprising: CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87, a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, 64, 72, 80, and 88, and a CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89; and / or a light chain variable region comprising: CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90, a CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, 67, 75, 83, and 91, and a CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92 (hereinafter sometimes referred to as a clone-derived antibody / antibody fragment). In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: a heavy chain variable region comprising: CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 47, 55, 63, 71, 79, and 87, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 40, 48, 56, 64, 72, 80, and 88, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 41, 49, 57, 65, 73, 81, and 89; and / or a light chain variable region comprising: CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 42, 50, 58, 66, 74, 82, and 90, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 51, 59, 67, 75, 83, and 91, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 44, 52, 60, 68, 76, 84, and 92; (hereinafter, sometimes referred to as clone-derived antibody / antibody fragment).

[0100] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: a heavy chain variable region comprising CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, and 63, CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, and 64, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, and 65; and / or a light chain variable region comprising CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, and 66, CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, and 67, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, and 68 (hereinafter sometimes referred to as a clone-derived antibody / antibody fragment). In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: a heavy chain variable region comprising CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 39, 47, 55, and 63, CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 40, 48, 56, and 64, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 41, 49, 57, and 65; and / or a light chain variable region comprising CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 42, 50, 58, and 66, CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 51, 59, and 67, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 44, 52, 60, and 68 (hereinafter sometimes referred to as a clone-derived antibody / antibody fragment).

[0101] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure comprises: a heavy chain variable region comprising CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 71, 79, and 87, CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 80, and 88, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 81, and 89; and / or a light chain variable region comprising CDR1 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 82, and 90, CDR2 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 75, 83, and 91, and CDR3 comprising (or consisting of) an amino acid sequence selected from the group consisting of SEQ ID NOs: 76, 84, and 92 (hereinafter sometimes referred to as a clone-derived antibody / antibody fragment).

[0102] As used herein, "comprising a predetermined amino acid sequence" encompasses "consisting of the predetermined amino acid sequence" and "consisting of an amino acid sequence in which one or more amino acid residues have been added to the predetermined amino acid sequence."

[0103] As used herein, "substitution" may be a conservative substitution or a non-conservative substitution, and is preferably a conservative substitution. Conservative substitution is known to those skilled in the art and refers to a substitution that does not change the biological activity of the resulting molecule. Examples of conservative amino acid substitutions include alanine to glycine or serine substitution, arginine to lysine or histidine substitution, asparagine to glutamine or histidine substitution, aspartic acid to glutamic acid or asparagine substitution, cysteine ​​to serine or alanine substitution, glutamine to asparagine substitution, glutamic acid to aspartic acid or glutamine substitution, glycine to alanine substitution, histidine to asparagine or glutamine substitution, isoleucine to leucine or valine substitution. , leucine to isoleucine or valine substitution, lysine to arginine or histidine substitution, methionine to leucine, isoleucine or tyrosine substitution, phenylalanine to tyrosine, methionine or leucine substitution, proline to alanine substitution, serine to threonine substitution, threonine to serine substitution, tryptophan to tyrosine or phenylalanine substitution, tyrosine to tryptophan or phenylalanine substitution, and valine to isoleucine or leucine substitution.

[0104] As used herein, "sequence identity" refers to the percentage of amino acid residues that match between two sequences that are optimally aligned (maximum identity) across the entire region of the sequences being compared. In optimal alignment of two sequences, one of the sequences may have additions or deletions (e.g., gaps). Sequence identity can be calculated, for example, by creating an alignment using the Clustal W algorithm (Nucleic Acid Res., 22(22):4673-4680(1994)). Sequence identity can be calculated using sequence analysis software such as Vector NTI and GENETYX-MAC, or analysis tools provided in public databases (e.g., http: / / www.ddbj.nig.ac.jp).

[0105] In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure is a monoclonal antibody or antibody fragment thereof that competes with the clone 1-derived antibody / antibody fragment, clone 2-derived antibody / antibody fragment, clone 3-derived antibody / antibody fragment, clone 4-derived antibody / antibody fragment, clone 5-derived antibody / antibody fragment, clone 6-derived antibody / antibody fragment, clone 7-derived antibody / antibody fragment, clone 8-derived antibody / antibody fragment, or clone-derived antibody / antibody fragment, described above, for binding to the HA stem region (or LAH region). In one embodiment, the monoclonal antibody or antibody fragment thereof of the present disclosure is a monoclonal antibody or antibody fragment thereof that competes with clone 1-derived antibody / antibody fragment, clone 2-derived antibody / antibody fragment, clone 3-derived antibody / antibody fragment, clone 4-derived antibody / antibody fragment, clone 5-derived antibody / antibody fragment, clone 6-derived antibody / antibody fragment, clone 7-derived antibody / antibody fragment, clone 8-derived antibody / antibody fragment, or clone-derived antibody / antibody fragment for binding to a polypeptide consisting of an amino acid sequence selected from the amino acid sequences of SEQ ID NOs: 1 to 18 (or SEQ ID NOs: 19 to 36).

[0106] As used herein, "compete" means that a monoclonal antibody or antibody fragment thereof competes with a reference antibody (e.g., an antibody / antibody fragment derived from clone 1, an antibody / antibody fragment derived from clone 2, an antibody / antibody fragment derived from clone 3, an antibody / antibody fragment derived from clone 4, an antibody / antibody fragment derived from clone 5, an antibody / antibody fragment derived from clone 6, an antibody / antibody fragment derived from clone 7, or an antibody / antibody fragment derived from clone 8) in a binding assay using a polypeptide comprising a portion or all of the HA stem region (or LAH region) (e.g., a polypeptide consisting of an amino acid sequence selected from the amino acid sequences of SEQ ID NOS: 1-18 or 19-36). For example, a test antibody or antibody fragment thereof "competes" with a reference antibody if it reduces binding of the reference antibody to a polypeptide comprising a portion or all of the HA stem region (or LAH region) in a binding assay. An antibody or antibody fragment that competes with a reference antibody reduces the binding of the reference antibody to an antigen by, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% or more. Competitive binding assays can be performed by conventional methods, such as ELISA, flow cytometry, surface plasmon resonance (SPR), and bio-layer interferometry (BLI).

[0107] Antigen binding can be confirmed by various assay methods, such as surface plasmon resonance (SPR), Western blotting, direct or indirect sandwich assays, flow cytometry, and immunoprecipitation assays (Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. 1987, pp. 147-158).

[0108] Antigen binding strength can be determined by adding one step (antigen-antibody binding dissociation step) to a standard ELISA method. Thiocyanate is used to dissociate antigen-antibody binding, and the strength of binding strength is determined by the level of thiocyanate concentration at which the dissociation occurs. The antibody used is a concentration range that is highly linear and sensitive to changes near the midpoint of the standard ELISA reaction curve. Thiocyanate concentrations can be calculated by comparing one or two levels of concentration with no treatment and calculating the thiocyanate resistance rate (%), or by varying multiple concentrations and calculating the concentration at which 50% inhibition (AI50) is achieved. Generally, if the epitope and antigen are the same, stronger binding strength can be expected to result in higher biological activity. In the case of the antibodies of the present invention, this test is a useful tool for predicting efficacy against virus strains that exhibit cross-reactivity.

[0109] Binding affinity can be determined using the SPR method. Devices that measure interactions between substances using SPR generally employ a Kretschmann configuration using a prism. When polarized light is irradiated so as to cause total reflection on the metal thin film surface of a sensor chip, an SPR signal is observed in which the reflected light intensity is reduced in a portion of the reflected light. The angle at which the SPR signal is generated varies depending on the mass on the sensor chip, and the angle at which the SPR signal is generated changes as the molecule (ligand) immobilized on the sensor chip binds or dissociates with the added molecule (analyte). Measurement results are obtained as a sensorgram showing the change in angle of the SPR signal and the response units (RU) converted from the change in angle over time. By fitting the acquired binding and dissociation sensorgrams to a theoretical curve, the binding rate constant (ka), dissociation rate constant (kd), and dissociation constant (KD = kd / ka) of the antibody to the antigen can be determined. In certain embodiments, the SPR method is performed under the conditions described in the Examples.

[0110] When used as a medical antibody, the monoclonal antibody or antibody fragment thereof of the present disclosure preferably has a reduced risk of exhibiting antigenicity when administered to humans. The monoclonal antibody or antibody fragment thereof may be a fully human antibody, a humanized antibody, or a chimeric antibody (e.g., a mouse-human chimeric antibody), or a fragment thereof. When used for quality control purposes in vaccine production, the monoclonal antibody or antibody fragment thereof of the present disclosure may be a mouse antibody, a chimeric antibody (e.g., a mouse-human chimeric antibody), a humanized antibody, a fully human antibody, or a fragment thereof.

[0111] The monoclonal antibody or antibody fragment thereof of the present disclosure may be a multispecific antibody or a fragment thereof that binds to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 to 18 or 19 to 36 and to an antigen different from this polypeptide.

[0112] The monoclonal antibody or antibody fragment thereof may be conjugated with a drug, which may be a low molecular weight compound, a peptide, a nucleic acid, or the like.

[0113] In the present disclosure, the term "pharmaceutical composition containing a monoclonal antibody or an antibody fragment thereof" means a pharmaceutical composition containing at least one monoclonal antibody or at least one antibody fragment thereof, and includes, for example, a pharmaceutical composition containing one type of monoclonal antibody, a pharmaceutical composition containing two or more types of monoclonal antibodies, a pharmaceutical composition containing one type of antibody fragment, a pharmaceutical composition containing two or more types of antibody fragments, a pharmaceutical composition containing one type of monoclonal antibody and one type of antibody fragment, and a pharmaceutical composition containing two or more types of monoclonal antibodies and two or more types of antibody fragments.

[0114] In addition to the monoclonal antibody or antibody fragment thereof, the pharmaceutical composition may contain pharmaceutically acceptable carriers or additives such as sterile water, physiological saline, stabilizers, excipients, antioxidants, buffers, preservatives, chelating agents, etc.

[0115] The administration form and route of a monoclonal antibody or its antibody fragment to a subject can be appropriately determined depending on the purpose of administration, the condition of the subject, etc. Administration forms include injections, transdermal preparations, inhalants, nasal drops, oral preparations, etc. In some embodiments, the administration form is injections. Administration routes include intravenous, intraarterial, subcutaneous, intramuscular, transdermal, nasal, and oral administration. In some embodiments, the administration route is intravenous administration (e.g., into the antecubital fossa or other peripheral vein) or subcutaneous administration.

[0116] When a monoclonal antibody or an antibody fragment thereof is administered to a subject, it may be administered alone or in combination with multiple antibodies, such as antibodies that bind to the HA stem regions (or LAH regions) of two or more different influenza A virus HA subtypes belonging to phylogenetic group 1, antibodies that bind to the HA stem regions (or LAH regions) of two or more different influenza A virus HA subtypes belonging to phylogenetic group 1, or a combination of these antibodies.

[0117] The dosage of the monoclonal antibody or its antibody fragment can be adjusted appropriately depending on the purpose of administration, the age and body weight of the subject, etc. The dosage can be selected, for example, within the range of 0.0001 mg to 1,000 mg / kg body weight as a single dose, and can also be selected within the range of 0.001 to 100,000 mg per patient, but is not limited thereto. In the present disclosure, subjects to be administered include mammals (e.g., humans, mice, rats, hamsters, guinea pigs, rabbits, cats, dogs, pigs, cows, horses, sheep, and monkeys), preferably humans.

[0118] The administration schedule of a monoclonal antibody or its antibody fragment can be adjusted appropriately depending on the purpose of administration, the age and weight of the subject, etc. For example, the frequency of administration is usually in the range of once per week to once per three months, more preferably once per two weeks to once per ten weeks, e.g., once per four to eight weeks. For preventive treatment, administration is usually preferably once per month to once per two to three months, or less frequently. The administration frequency may be one time, or multiple times (e.g., two to five times) at intervals of several days or weeks.

[0119] In one embodiment, the present disclosure provides a monoclonal antibody or antibody fragment that binds to an epitope consisting of several to a dozen or so amino acids that are common or similar to the amino acid sequence of an influenza virus HA stem region (e.g., SEQ ID NOS: 1-18) or the long alpha helix region (LAH region, SEQ ID NOS: 19-36) in the influenza virus HA stem region (e.g., SEQ ID NOS: 1-18). In one embodiment, the present disclosure provides a therapeutic or preventive agent for influenza virus infection, comprising a monoclonal antibody or antibody fragment that binds to an epitope consisting of several to a dozen or so amino acids that are common or similar to the amino acid sequence of an influenza virus HA stem region or the LAH amino acid sequence of an influenza virus HA stem region. In one embodiment, the present disclosure provides a method for detecting or quantifying an HA-derived influenza virus vaccine antigen, comprising contacting a sample with a monoclonal antibody or antibody fragment that binds to a polypeptide consisting of several to a dozen or so amino acids that are common or similar to the amino acid sequence of an influenza virus HA stem region or the LAH amino acid sequence of an influenza virus HA stem region. In one embodiment, the present disclosure relates to a method for measuring anti-LAH antibody titers in human blood, which is developed using the monoclonal or chimeric antibody of the present invention as a positive control.

[0120] The monoclonal antibody or antibody fragment thereof of the present disclosure can detect or quantify influenza HA antigens (e.g., fusion influenza HA antigens) and can be useful, for example, for quality control of influenza vaccines containing the same or intermediate products during their production. Quality control includes specification control and process control. In one aspect, the present disclosure provides a method for detecting or quantifying a fusion influenza HA antigen, comprising contacting a sample with the monoclonal antibody or antibody fragment thereof of the present disclosure. The sample can be, for example, an influenza vaccine containing a fusion influenza HA antigen or a sample obtained during its production process. Detection or quantification can be performed, for example, by ELISA or slot blot. Note that the fusion influenza HA antigen includes the entire stem region and is an antigen obtained by acid-treating influenza A HA antigen. For example, the stem region including the LAH region can be detected by using an antibody that recognizes the LAH region, which is a part of the fusion influenza HA antigen. In one embodiment, the fusion influenza HA antigen can be produced according to WO 2020 / 179797. In one embodiment, the membrane-fused influenza HA antigen is obtained by treating an influenza A whole particle vaccine with ether to remove lipid components that become pyrogens, and then subjecting the obtained influenza A HA antigen to an acid treatment and optionally to a formalin treatment. In one embodiment, the membrane-fused influenza HA antigen has a form in which the HA stem region is exposed to the outside.

[0121] The content of influenza HA antigen (not membrane-fused) in common inactivated influenza vaccines is quantified by the SRD test (single radial immunodiffusion). In the SRD test, a well is drilled in a gel containing an antibody, and the antigen is added. The antigen diffuses radially from the well, forming a precipitation ring at the equilibrium point between the antibody and antigen. The antigen concentration is determined by measuring the diameter of the ring. The SRD test is a commonly used method for testing the potency of inactivated influenza vaccines and is quantified using commercially available standard antigens or reference antisera. However, because membrane-fused influenza HA antigens have a different three-dimensional structure from regular influenza HA antigens and have different reactivity with reference antisera, it is thought that the SRD test cannot accurately measure their content. The monoclonal antibody or antibody fragment of the present invention binds to an epitope consisting of several to a dozen amino acids that are common or similar to each other in the LAH amino acid sequence of the HA stem region. Therefore, the monoclonal antibody or antibody fragment thereof is suitable for quantifying the content of a membrane-fused influenza HA antigen by a slot blot test or an ELISA test, and can be used as a titer test for a membrane-fused influenza HA antigen.

[0122] In one embodiment, the membrane-fused influenza HA antigen is obtained by a method comprising the following steps: (1) treating whole influenza A particles with ether to obtain an influenza A HA antigen; (2) subjecting the obtained influenza A HA antigen to an acid treatment; and (3) subsequently, optionally subjecting the antigen to a formalin treatment.

[0123] In one embodiment, the membrane-fused influenza HA antigen is obtained by a method comprising the following steps: (1) treating whole influenza A particles to remove lipid components that are pyrogens to obtain an influenza A HA antigen; (2) subjecting the obtained influenza A HA antigen to an acid treatment; and (3) subsequently, optionally subjecting the resulting influenza A HA antigen to a formalin treatment.

[0124] The acid treatment is not particularly limited, but may have a pH of 2.0 to 6.5, preferably 3.0 to 6.5, more preferably 4.0 to 6.0, and even more preferably 4.4 to 5.8. Specific examples include pH 2.0 to 2.9, 2.0 to 4.0, 2.0 to 5.0, 2.0 to 6.0, 3.0 to 4.0, 3.0 to 5.0, 3.0 to 6.0, 4.0 to 5.8, 4.0 to 6.5, 5.0 to 6.5, or 6.0 to 6.5. The acid used for the acid treatment is not particularly limited, but examples include phosphoric acid, citric acid, maleic acid, and hydrochloric acid.

[0125] The temperature during the acid treatment is, for example, 0°C to 75°C, preferably 10°C to 60°C, more preferably 20°C to 45°C, and even more preferably 25°C to 42°C. Specific examples include 0°C to 20°C, 5°C to 25°C, 10°C to 30°C, 15°C to 35°C, 20°C to 37°C, 25°C to 37°C, 30°C to 50°C, 38°C to 55°C, 38°C to 60°C, 38°C to 65°C, 38°C to 70°C, 38°C to 75°C, 40°C to 55°C, 40°C to 60°C, 40°C to 65°C, 40°C to 70°C, 40°C to 75°C, 42°C to 55°C, 42°C to 60°C, 42°C to 65°C, 42°C to 70°C, 42°C to 75°C, 45°C to 55°C, 45°C to 60°C, 45°C to 65°C, 45°C to 70°C, and 45°C to 75°C. The treatment time is, for example, 5 to 120 minutes, preferably 15 to 60 minutes, and more preferably 20 to 45 minutes.Specific examples include 5 to 60 minutes, 20 to 60 minutes, 15 to 120 minutes, 15 to 45 minutes, 20 to 60 minutes, 20 to 120 minutes, 45 to 120 minutes, or 60 to 120 minutes.

[0126] The monoclonal antibody or antibody fragment thereof of the present disclosure can be used to construct a test system for antibody titer or avidity and as a positive control during measurement when measuring antibody titer or antibody binding strength in the blood after vaccine administration. In this case, the monoclonal antibody or antibody fragment thereof of the present disclosure preferably binds to the LAH region. A method for measuring human antibody titer against the LAH peptide, which is a membrane-fused HA antigen portion essential for clinical development of vaccines, can be established and quantified. In particular, there are limitations to the development of methods for measuring blood antibody titer at the current technical level, due to the lack of a positive control serum. However, using the human monoclonal antibody or chimeric antibody of the present invention as a positive control makes quantitative evaluation possible, thereby reducing obstacles to development.

[0127] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples in any way.

[0128] 1. Production of mouse monoclonal antibodies against H3N2 Using mice infected and vaccinated with the A / H3N2 influenza virus X31 strain, mouse B cells were fused with myeloma cells by the hybridoma method, and clones 1 and 2 were isolated.

[0129] 2. Generation of mouse monoclonal antibodies against H1N1. HA-binding B cells were isolated from the lung tissue of mice infected with the A / H1N1 influenza virus A / Narita / 1 / 2009 strain using a flow cytometer. Mouse antibody genes were cloned from the isolated B cells to generate monoclonal antibodies Clone 3 and Clone 4.

[0130] 3. Production of human monoclonal antibodies HA-binding memory B cells were isolated from peripheral blood mononuclear cells of healthy individuals using a flow cytometer. To produce clone 5, human antibody genes were cloned from the isolated cells to produce monoclonal antibodies. To produce clones 6 and 7, the cells were cultured in a single cell culture system, and human antibody genes were cloned from the cultured cells to produce monoclonal antibodies.

[0131] 4. Production of chimeric antibody Based on the amino acid sequences of the heavy and light chain variable regions of the mouse monoclonal antibody Clone 4 antibody and the amino acid sequences of the heavy and light chain constant regions of a human antibody with a known sequence registered in a gene bank (heavy chain: accession number QDA39867.1, light chain: accession number P01834.2), a gene for a chimeric antibody in which the variable region is Clone 4 and the constant region is human was produced. This was then expressed in CHO cells using a plasmid, and the chimeric antibody (Clone 8) was purified.

[0132] 5. Measurement of antibody titer by ELISA The LAH antibody titer of human or mouse monoclonal antibodies (clones 1 to 7) was measured by ELISA (Enzyme-Linked Immunosorbent Assay) according to the method described below. Specifically, recombinant HA antigens (A / X-31 (H3N2), A / Victoria / 361 / 2011 (H3N2), A / Puerto Rico / 8 / 1934 (H1N1), A / Narita / 1 / 2009 (H1N1pdm09), A / NIBRG-14 (H5N1), and A / Anhui / 1 / 2013 (H7N9) were prepared with reference to Onodera T et al. PNAS. 109 (7) 2485-2490. (2012)), A / Singapore / INFIMH-16-0019 / 2016 (H3N2), A / Kansas / 14 / 2017 (H3N2), and A / Michigan / 45 / 2015 (H7N9) were prepared with reference to Onodera T et al. PNAS. 109 (7) 2485-2490. (2012)). (H1N1pdm09), A / Brisbane / 02 / 2018 (H1N1pdm09) was prepared with reference to Onodera T et al. Immunity. 54(10):2385-2398.e10. (2021)) was dissolved in phosphate-buffered saline at 5 μg / ml and added to a 96-well plate for incubation. After washing each well with phosphate-buffered saline, phosphate-buffered saline containing 1% bovine serum albumin was added and incubated. Serial dilutions of known concentrations of human or mouse monoclonal antibodies (clones 1-7) were added to each well of the plate and incubated. After washing each well of the plate with phosphate-buffered saline (containing 0.05% Tween 20), peroxidase-labeled anti-human or anti-mouse IgG antibody (both Southern Biotech) diluted in phosphate-buffered saline containing 0.05% Tween 20 and 1% bovine serum albumin was added to each well and incubated.After washing each well of the plate with phosphate-buffered saline (containing 0.05% Tween 20), a substrate was prepared by adding o-phenylendiamine tablets (Sigma) and hydrogen peroxide to citrate buffer (pH 5.0) and adding it to each well. After incubation, the reaction was stopped with 2N sulfuric acid, and the absorbance at 490 nm was measured using a microplate reader (Biorad).

[0133] 6-1. Confirmation of cross-reactivity of monoclonal antibodies against the LAH region Using the method described in 5 above, the antibody titers of human monoclonal antibodies (clones 5-7) and mouse monoclonal antibodies (clones 1-4) were measured by ELISA. A graph was created with the ELISA measurement value (absorbance) of each antibody on the vertical axis and the reciprocal of the antibody concentration on the horizontal axis, and the area under the curve (AUC) of each curve was calculated. The results are shown in Figure 1.

[0134] Human monoclonal antibodies Clone 6 and Clone 7 were confirmed to bind to H1N1, H3N2, H5N1, and H7N9 antigens, suggesting broad binding to both phylogenetic groups 1 and 2. Human monoclonal antibody Clone 5 was confirmed to bind to H3N2 and H7N9, suggesting binding to phylogenetic group 2. Mouse monoclonal antibodies Clone 1 and Clone 2 were confirmed to bind to H3N2 and showed weak binding to H7N9, suggesting binding to phylogenetic group 2. Mouse monoclonal antibodies Clone 3 and Clone 4 were confirmed to bind to H1N1 and H5N1, suggesting binding to phylogenetic group 1.

[0135] The sequence of the LAH portion of the antigen corresponding to part of the stem (long alpha helix) used to confirm cross-reactivity and the strain from which the LAH was derived are shown below.

[0136] 6-2. Analysis of binding between monoclonal antibodies and antigenic proteins Following the method described in 5 above, the antibody titers of human monoclonal antibodies (clones 6 and 7) were measured by ELISA using 19 types of recombinant HA antigens. To compare the amount of recombinant monoclonal antibody bound to each HA antigen, AUC values ​​were calculated, and the results are shown in a heat map. The results are shown in Figure 2 and the table below.

[0137] The human monoclonal antibody Clone 6 was confirmed to bind to H1N1, H2N2, H3N2, H4N6, H5N1, H6N1, H7N9, H8N4, H9N2, H10N7, H11N9, H14N5, H15N9, H16N3, H17N10, and H18N11 antigens, suggesting broad binding to both phylogenetic groups 1 and 2. The human monoclonal antibody Clone 7 was confirmed to bind to H1N1, H2N2, H3N2, H4N6, H5N1, H6N1, H7N9, H8N4, H9N2, H10N7, H11N9, H12N5, H13N6, H14N5, H15N9, H16N3, H17N10, and H18N11 antigens, suggesting broad binding to both phylogenetic groups 1 and 2. Clones 6 and 7 exhibit broad binding activity to H1-H18 antigens, suggesting they may exhibit protective activity against a broad range of antigens. The 19 recombinant HA antigens used in the assay are listed in the table below. All 19 recombinant HA antigens were prepared with reference to Saito S et al. PLoS Pathog 15(1): e1007427.

[0138] 7. Quantitative Method for Quantifying Human Anti-LAH Antibody Titers by ELISA It is desirable to use a standard serum with a known antibody titer as a positive control for measuring antibody titers in human blood. However, in the absence of human LAH immune serum, there is no human anti-LAH standard serum, nor is there any immune serum to be measured. Even under these limited conditions, the feasibility of quantifying human anti-LAH antibody titers was confirmed using a model system using monoclonal antibodies. Using the human monoclonal antibody Clone 6 as the standard, arbitrary titers (AU) were established for H1 LAH and H3 LAH in ELISA. The anti-H1 LAH and H3 LAH antibody titers were quantified using the calibration curve method with Clone 8, a chimeric antibody against H1 LAH, and Clone 5, a human monoclonal antibody against H3 LAH, as samples.

[0139] (1) Determination of Arbitrary Titer (AU) in ELISA Using Clone 6 A graph was plotted with absorbance on the vertical axis and logarithmic values ​​of antibody concentration on the horizontal axis, and the antibody concentration corresponding to the midpoint (IC50) of the obtained sigmoid curve was designated as 1 arbitrary titer (AU / mL) (Clone 6 anti-H1-LAH antibody: 4.96 ng Clone 6 / AU; Clone 6 anti-H3 LAH antibody: 11.08 ng Clone 6 / mL) ( FIG. 3 ).

[0140] (2) Preparation of a calibration curve using Clone 6 and quantification of samples. Absorbance was plotted on the vertical axis and logarithmic titer on the horizontal axis, and the resulting sigmoid curve was used to calculate titer values. For the samples (Clone 8 (anti-H1 LAH antibody) and Clone 5 (anti-H3 LAH antibody)), absorbance was measured at multiple antibody concentrations. The absorbance values ​​closest to the midpoint (IC50) of the calibration sigmoid curve (anti-H1 LAH antibody titer: 0.743, anti-H3 LAH antibody titer: 0.908) were used (Clone 8: 0.538; Clone 5: 0.877). The titers (Clone 8: 0.589 AU / mL; Clone 5: 0.920 AU / mL) at those antibody concentrations (Clone 8: 3.906 ng / mL; Clone 5: 15.625 ng / mL) were calculated using the calibration curve formula (Figure 4). In a model system using monoclonal antibodies, it was confirmed that human antibody titers can be quantified using the calibration curve method.

[0141] (3) Quantification of serum samples using a standard curve for Clone 6. To measure antibody titers in actual clinical samples, serum samples diluted to three concentrations (e.g., 400-, 800-, and 1200-fold dilutions) are added to the same ELISA plate as the dilution series of Clone 6 standard with known titers. The absorbance reading closest to the midpoint (IC50) of the sigmoidal curve of the standard curve is selected, and the titer at that sample concentration is calculated using the standard curve formula. This result is multiplied by the dilution factor to obtain the serum antibody titer. While this system uses a monoclonal antibody as the standard, it is also possible to use a standard serum for actual blood antibody titer measurements, with the horizontal axis plotted as the logarithm of the standard serum dilution factor.

[0142] 8. Protective Effect of Passive Immunity by Monoclonal Antibodies on Infection We used mice to examine whether administration of monoclonal antibodies confers protective effect against infection. (1) Protective Effect against H1N1 Virus Strains Mice were assigned to seven groups (four mice per group)—one control group administered PBS, and one test group administered four types of monoclonal antibodies (clone 3, clone 4, clone 6, and clone 7) at 5 mg / kg body weight or 10 mg / kg body weight (clone 6 was administered only in the 10 mg / kg body weight group). These antibodies were intraperitoneally administered 24 hours before infection and challenged with the A / Guangdong-Maonan / SWL1536 / 2019 (H1N1pdm09) strain. The efficacy of the antibodies was evaluated using the weight change rate (Figure 5) and survival rate (Figure 6) of the mice after the challenge.

[0143] In the negative control PBS-administered group, weight loss began three days after virus inoculation and continued until the eighth day, showing a significant weight loss of more than 20%, with three animals dying on days six and seven after inoculation. One surviving animal subsequently began to gain weight, but even 12 days later, its weight had only recovered to 90% of its pre-inoculation weight. In the antibody-administered group, all animals lost about 5% of their weight on day three after virus inoculation, but began to gain weight from day five onwards, and all animals survived, demonstrating a protective effect against infection.

[0144] (2) Protective effect against H3N2 virus strains Mice were divided into three groups: a control group administered PBS, and test groups administered two types of monoclonal antibodies (clone 6 and clone 7) at 4 mg / kg body weight each. These were intraperitoneally administered 24 hours before infection and then challenged with the A / X31 (H3N2) strain. The efficacy of the antibodies was evaluated based on the weight change rate (Figure 7) and survival rate (Figure 8) of the mice after the challenge.

[0145] In the negative control PBS-administered group, weight loss was significant from day 6 to day 9 after virus inoculation, showing a 30% decrease, and all animals died by day 8. In the antibody-administered groups, weight loss began on day 5 after virus inoculation, with Clone 6 continuing to lose weight until day 7 and Clone 7 until day 8. Thereafter, weight began to increase and all animals survived, demonstrating a protective effect against infection.

[0146] 9. Measurement of Avidity The avidity of LAH peptide antigens and antibodies is measured by adding an additional step to the standard ELISA process: dissociating the antibody from the antigen. An antigen-coated plate is prepared using the same method as standard ELISA, and a sample containing the test antibody is reacted. The sample is diluted to an appropriate concentration that produces a color development of 0.7±0.3 OD490 in standard ELISA. The antibody is then dissociated by treatment with sodium thiocyanate (NaSCN) solution. The plate is washed three times with PBS containing 0.05% Tween 20, and 100 μL / well of PBS containing 1 mol / L or 2 mol / L sodium thiocyanate (NaSCN) is added. After incubation at room temperature for 30 minutes, the plate is washed three times with PBS containing 0.05% Tween 20. The amount of antibody remaining on the plate without dissociation is measured using a labeled secondary antibody and a chromogenic substrate in the usual manner, and the ratios of antibodies with high, medium, and low binding affinity are calculated by comparing with the NaSCN-untreated control using the following formula: High binding affinity ratio: (OD490 2 mol / L-treated serum / OD490 untreated serum) x 100% Medium binding affinity ratio: (OD490 1 mol / L-treated serum / OD490 2 mol / L-treated serum) x 100% Low binding affinity ratio: (OD490 untreated serum / OD490 1 mol / L-treated serum) x 100%

[0147] 10. CDR Analysis The nucleotide sequences of the genes in clones 1 to 8 were obtained with reference to previous papers (Tiller et al., J. Immunol. Methods., 2008 and Tiller et al., J. Immunol. Methods., 2009). RNA was extracted from HA-binding B cells, and cDNA was synthesized by reverse transcription. Human / mouse IgG heavy chain / light chain regions were amplified by PCR using the synthesized cDNA as a template. The amplified PCR products were subjected to Sanger sequencing to identify the antibody nucleotide sequences. CDR information for clones 1 to 8 was obtained by comparing the identified nucleotide sequences with the antibody gene database (IMGT: International ImMunoGeneTics database).

[0148] The heavy chain CDRs 1 to 3 (H-CDRs 1 to 3), light chain CDRs 1 to 3 (L-CDRs 1 to 3), and heavy chain variable region (V-CDRs) of the monoclonal antibodies (clones 1 to 8) were H ), and the light chain variable region (V L The amino acid sequences of the nucleotides 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32

[0149] 11. Quality Control of Influenza Vaccines (Slot Blot) (1) Production of Membrane Fusion Influenza Vaccines 1. Preparation of HA Split Vaccines H3N2 influenza virus particles (X31 strain) or H1N1 influenza virus particles (A / Puerto Rico / 8 / 34 strain) suspended in phosphate-buffered saline were added with Tween 80 to a final concentration of 0.2%. Diethyl ether was added to further suspend the virus. The mixture was allowed to stand until the aqueous and diethyl ether layers completely separated, after which the diethyl ether layer was removed. This ether extraction was repeated, and the diethyl ether remaining in the recovered aqueous layer was evaporated under normal pressure to yield the HA split vaccine. 2. Acid Treatment The HA split vaccine was suspended in phosphate-buffered saline and then acidified by adding 0.15 M citrate buffer (pH 3.5) to adjust the pH to 5.0. After allowing to stand at room temperature for 30 minutes, 1 M Tris buffer (pH 0.0) was added to adjust the pH to 7.3. The mixture was then centrifuged to produce a fusion-type HA split vaccine. Formalin was added to the prepared fusion-type HA split vaccine to a final concentration of 0.05%, and the mixture was allowed to stand for several days. (2) Detection and Quantification of the Fusion-Type Influenza Vaccine. The H1 fusion-type influenza HA antigen prepared in (1) was detected and quantified by slot blot as follows. Specifically, a dilution solution containing H1 fusion-type influenza HA antigen in phosphate buffer (serial dilutions of a 300 ng / mL solution at a common ratio of 1.6; 45.8 ng / mL to 300 ng / mL) and a dilution solution containing the test sample in phosphate buffer (approximately 150 ng / mL) were applied to a membrane (Immobilon-P transfer membrane, Merck) attached to a 48-well slot blot device. Then, the dilution solution was 10-fold diluted with phosphate buffer and then quantified using a Blocker™. TMBlocking was performed with BSA (10X) (Thermofisher Scientific). The membrane was incubated with mouse monoclonal antibody clone 3 (1 μg / ml) diluted in phosphate buffer supplemented with 0.05% Tween 20 and then washed with phosphate buffer supplemented with 0.05% Tween 20. The membrane was probed with a fluorescently labeled secondary antibody (Thermofisher Scientific), washed with phosphate buffer supplemented with 0.05% Tween 20, and visualized using a ChemiDoc Touch MP (Bio-Rad). As shown in Figure 9, the H1 fusion influenza HA antigen reacted with mouse monoclonal antibody clone 3 in a concentration-dependent manner in slot blots, demonstrating that this monoclonal antibody can be used to detect and quantify the H1 fusion influenza HA antigen. Furthermore, as shown in Figure 10, it was demonstrated that the H3 fusion influenza HA antigen produced in (1) can also be similarly detected and quantified using mouse monoclonal antibody clone 1.

[0150] 12. Quality control of influenza vaccines (ELISA) The H1 fusion influenza HA antigen produced in 11 above was detected and quantified by ELISA as follows: Mouse monoclonal antibody clone 3 (5 μg / mL) diluted in carbonate buffer was attached to a 96-well plate, and a dilution solution containing H1 fusion influenza HA antigen in phosphate buffer (serial dilution of a 2000 ng / mL solution at a common ratio of 3; 34 pg / mL to 2000 ng / mL) and a dilution solution containing a test sample in phosphate buffer (approximately 50 ng / mL) were added. TMBlocking was performed with 10X BSA (Thermofisher Scientific). Anti-H1 fusogenic influenza HA antigen polyclonal antibody prepared from rabbit antiserum was diluted 2000-fold with phosphate buffer supplemented with 0.05% Tween 20 and added to the blocked plate for incubation. After washing the plate with phosphate buffer supplemented with 0.05% Tween 20, a secondary antibody (Anti-rabbit IgG, HRP-Linked Antibody, Cell Signaling) diluted 1000-fold with phosphate buffer supplemented with 0.05% Tween 20 was added and incubated. The plate was then washed with phosphate buffer supplemented with 0.05% Tween 20, and a substrate solution (TMB 1-Component Microwell Peroxidase Substrate, SureBlue Reserve, Ceracare Life Sciences) was added and incubated. A reaction stop solution (TMB Stop Solution, Ceracare Life Sciences) was added to this solution, and the enzymatic reaction product was measured using a microplate reader. As shown in Figure 11, the H1 membrane fusion influenza HA antigen reacted with mouse monoclonal antibody clone 3 in a concentration-dependent manner in ELISA, demonstrating that the monoclonal antibody can be used to detect and quantify the H1 membrane fusion influenza HA antigen. Furthermore, as shown in Figure 12, the mouse monoclonal antibody clone 1 was used to similarly detect and quantify the H3 membrane fusion influenza HA antigen produced in 11 above. It is believed that the methods of 11 and 12 above can be used to similarly detect and quantify H1 membrane fusion influenza HA antigens not only with clone 3, which binds to the H1 subtype, but also with clones 4, 6, 7, and 8. It is also believed that the methods of 11 and 12 above can be used to similarly detect and quantify H3 membrane fusion influenza HA antigens not only with clone 1, which binds to the H3 subtype, but also with clones 2, 5, 6, and 7.The membrane-fused influenza HA antigen has a different three-dimensional structure from conventional influenza HA antigens and differs in reactivity with the reference antiserum in the SRD test, which is a conventional quantitative test. Therefore, it is thought that quantifying it using a conventional quantitative test would be difficult. However, the results of tests 11 and 12 indicate that it is possible to quantify the membrane-fused influenza HA antigen by performing a slot blot test or an ELISA test using the monoclonal antibody or antibody fragment of the present application.

[0151] The monoclonal antibodies or antibody fragments of the present disclosure are useful for treating or preventing influenza infection and for quality control during influenza vaccine production.

Claims

1. A monoclonal antibody or an antibody fragment thereof that binds to the hemagglutinin stem region (HA stem region) of influenza A virus.

2. The monoclonal antibody or antibody fragment thereof according to claim 1, which binds to a peptide consisting of at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 18.

3. A monoclonal antibody or an antibody fragment thereof according to claim 1 or 2, which binds to the LAH (long alpha helix) region of the HA stem region.

4. A monoclonal antibody or an antibody fragment thereof according to any one of claims 1 to 3, which binds to a peptide consisting of at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 36.

5. The monoclonal antibody or antibody fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87 in which one or two amino acid residues are independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, 64, 72, 80, and 88; a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89, and ... CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90, or an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90 in which one or two amino acid residues are independently substituted, deleted, added, or inserted; an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, 67, 75, 83, and 91; 5. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 4, comprising: a light chain variable region comprising a CDR2 comprising an amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted in a selected amino acid sequence; and a CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92, or an amino acid sequence in which one or two amino acid residues have been independently substituted, deleted, added, or inserted in an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92.

6. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 5, comprising: a heavy chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, 63, 71, 79, and 87, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, 64, 72, 80, and 88, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, 65, 73, 81, and 89; and / or a light chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, 66, 74, 82, and 90, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, 67, 75, 83, and 91, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, 68, 76, 84, and 92.

7. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 6, comprising: a heavy chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 55, and 63, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 48, 56, and 64, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49, 57, and 65; and / or a light chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 58, and 66, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 59, and 67, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 60, and 68.

8. The monoclonal antibody or antibody fragment thereof according to claims 1 to 6, comprising: a heavy chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 71, 79, and 87, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 72, 80, and 88, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 73, 81, and 89; and / or a light chain variable region comprising CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 82, and 90, CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 75, 83, and 91, and CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 76, 84, and 92.

9. (a) a heavy chain variable region comprising: a CDR1 comprising the amino acid sequence of SEQ ID NO: 47 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 48 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 49 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 50 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:52, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(b) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 55 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 56 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 57 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 58 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:60, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(c) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 63 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 64 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 65 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:68, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(d) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 71 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 72 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:76, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(e) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 79 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 80 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 81 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 84, or said amino acid sequence having one or two amino acid residues independently substituted, deleted, added, or inserted therein;or (f) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 87 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 88 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 89 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 90 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 91 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 5, comprising a light chain variable region including a CDR3 comprising the amino acid sequence of SEQ ID NO: 92 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence.

10. (a') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:47, CDR2 comprising the amino acid sequence of SEQ ID NO:48, and CDR3 comprising the amino acid sequence of SEQ ID NO:49, and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:50, CDR2 comprising the amino acid sequence of SEQ ID NO:51, and CDR3 comprising the amino acid sequence of SEQ ID NO:52; (b') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:55, CDR2 comprising the amino acid sequence of SEQ ID NO:56, and CDR3 comprising the amino acid sequence of SEQ ID NO:57, and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:58, CDR2 comprising the amino acid sequence of SEQ ID NO:59, and CDR3 comprising the amino acid sequence of SEQ ID NO:60; (c') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO:63, CDR2 comprising the amino acid sequence of SEQ ID NO:64, and CDR3 comprising the amino acid sequence of SEQ ID NO:65, and / or (d') a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 66, CDR2 comprising the amino acid sequence of SEQ ID NO: 67, and CDR3 comprising the amino acid sequence of SEQ ID NO: 68; (d') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 71, CDR2 comprising the amino acid sequence of SEQ ID NO: 72, and CDR3 comprising the amino acid sequence of SEQ ID NO: 73, and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 74, CDR2 comprising the amino acid sequence of SEQ ID NO: 75, and CDR3 comprising the amino acid sequence of SEQ ID NO: 76; (e') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 79, CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and CDR3 comprising the amino acid sequence of SEQ ID NO: 81, and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 82, CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and CDR3 comprising the amino acid sequence of SEQ ID NO: 84;or (f') a heavy chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 87, CDR2 comprising the amino acid sequence of SEQ ID NO: 88, and CDR3 comprising the amino acid sequence of SEQ ID NO: 89, and / or a light chain variable region comprising CDR1 comprising the amino acid sequence of SEQ ID NO: 90, CDR2 comprising the amino acid sequence of SEQ ID NO: 91, and CDR3 comprising the amino acid sequence of SEQ ID NO:

92. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 6, comprising:

11. (a'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:53, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:54; (b'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:61, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:62; (c'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:69, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:70; (d'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:77, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:78; (e'') The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 10, comprising: (a) a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 85, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 86; or (b'') a heavy chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 93, and / or a light chain variable region comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:

94.

12. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 11, comprising: (a''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:53 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO:54; (b'') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:61 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO:62; (c''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:69 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO:70; (d''') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:77 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO:78; (e'') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:85 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO:86; or (f'') a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:93 and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO:

94.

13. A monoclonal antibody or an antibody fragment thereof that competes with the monoclonal antibody or antibody fragment thereof described in any one of claims 5 to 12 for binding to the HA stem region.

14. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 13, which binds to the HA stem region of two or more influenza virus HA subtypes.

15. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 14, which binds to the HA stem region of an influenza A virus HA subtype belonging to phylogenetic group 1 and binds to the HA stem region of an influenza A virus HA subtype belonging to phylogenetic group 2.

16. A monoclonal antibody or an antibody fragment thereof according to any one of claims 1 to 15, which has the ability to protect against influenza A virus infection.

17. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 16, which is a murine antibody, a chimeric antibody, a humanized antibody, or a fully human antibody, or a fragment thereof.

18. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 7 and 9 to 17, which is a mouse antibody or a fragment thereof.

19. The monoclonal antibody or antibody fragment thereof according to any one of items 1 to 7 and 9 to 17, which is a chimeric antibody or a fragment thereof.

20. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 17, which is a fully human antibody or a fragment thereof.

21. A monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 20, comprising a modified constant region.

22. The monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 21, which is conjugated to a drug.

23. A pharmaceutical composition for treating or preventing influenza A virus infection, comprising the monoclonal antibody or its antibody fragment according to any one of claims 1 to 22.

24. The pharmaceutical composition according to claim 23, wherein the monoclonal antibody or antibody fragment thereof is a monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 17 and 20 to 22.

25. The pharmaceutical composition according to claim 23, wherein the monoclonal antibody or antibody fragment thereof is the monoclonal antibody or antibody fragment thereof according to claim 8.

26. A method for detecting or quantifying a membrane-fused influenza HA antigen, which comprises contacting a sample with the monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 22.

27. The monoclonal antibody or antibody fragment thereof comprises: (a) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 47 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 48 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 49 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 50 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 51 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:52, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(b) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 55 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 56 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 57 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 58 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 59 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:60, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(c) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 63 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 64 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 65 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 66 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 67 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:68, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(d) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 71 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 72 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 73 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 74 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 75 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:76, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;(e) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 79 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 80 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 81 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 82 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 83 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO: 84, or said amino acid sequence having one or two amino acid residues independently substituted, deleted, added, or inserted therein;(f) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 87 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 88 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and a CDR3 comprising the amino acid sequence of SEQ ID NO: 89 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 90 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a CDR2 comprising the amino acid sequence of SEQ ID NO: 91 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted; a light chain variable region comprising a CDR3 comprising the amino acid sequence of SEQ ID NO:92, or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted;or (g) a heavy chain variable region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 39 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 40 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 41 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and / or a CDR1 comprising the amino acid sequence of SEQ ID NO: 42 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, a CDR2 comprising the amino acid sequence of SEQ ID NO: 43 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted, and The method of claim 26, which is a monoclonal antibody or antibody fragment thereof according to any one of claims 1 to 4, or a combination thereof, comprising a light chain variable region including a CDR3 comprising the amino acid sequence of SEQ ID NO: 44 or an amino acid sequence in which one or two amino acid residues are independently substituted, deleted, added, or inserted in said amino acid sequence; 28. The method of claim 26 or 27, wherein the monoclonal antibody or antibody fragment is a combination of a first antibody and a second antibody as described below. First antibody) A monoclonal antibody or antibody fragment according to any one of claims 1 to 22; or a monoclonal antibody or antibody fragment, wherein the heavy chain variable region comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 39, CDR2 comprising the amino acid sequence of SEQ ID NO: 40, and CDR3 comprising the amino acid sequence of SEQ ID NO: 41, and the light chain variable region comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 42, CDR2 comprising the amino acid sequence of SEQ ID NO: 43, and CDR3 comprising the amino acid sequence of SEQ ID NO: 44; Second antibody) A monoclonal antibody or antibody fragment different from the first antibody, which binds to a peptide to which the first antibody can bind, the peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 18.